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GENERAL SUMMARY 
 
Complement C2 receptor trispanning (CRIT), a three transmembrane receptor, was first 
discovered on the surface of the parasite Schistosoma haematobium and formerly termed 
Schistosoma trispanning orphan receptor (Sh-TOR). This receptor acts as decoy C2-
binding receptor to protect the parasite from classical pathway-mediated complement 
attack by competing with C4 for the binding of C2. The first extracellular domain (ed1) 
proved to be the hot spot for the binding of C2.  
 
The first part of my work and the detailed results will be presented and discussed in 
Section I. Apart from Schistosoma, another parasite Trypanosoma cruzi and rat also 
express CRIT and show high sequence homology. The cloning of human CRIT was 
started by PCR with the templates from both genomic DNA and cDNA. The primers used 
were selected from the conserved region. The human CRIT nucleotide sequences from 
genomic DNA and cDNA are identical, implying that human CRIT is encoded by a 
single exon, and therefore an intronless gene. A phylogenetic analysis of the available 
CRIT genes giving a measure of their evolutionary distance shows that the parasite 
species are as far removed from their human host as is the rat sequence. This is thought to 
be an example of horizontal gene transfer (HGT) in terms of genetic transfer between 
host and parasite. In addition, the cellular distributions and localizations of human CRIT 
were determined by immonblotting and immunohistochemistry.  
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It has been showed that a major binding site for C2 is located on short almost identical 
peptide sequences of CRIT-ed1 and the β-chain of C4. The C2 domain(s) involved in 
these bindings, however, has remained unknown. Since most of the von Willebrand 
factor-A (vWFA) domains are components of the extracellular matrix and very often are 
the sites for protein-protein interaction in cell adhesion protein, such as integrins, the 
vWFA domain of C2 was speculated to be the potential site of interaction with CRIT and 
C4. To further address this question, the vWFA domain (amino acids 224-437) of C2 was 
cloned and the first functional recombinant vWFA protein was expressed and purified. 
Based on the functional data, the vWFA domain of C2 is a potential binding site for both 
C4 and CRIT, and this forms the major aspect of Section II.  
 
The major findings of the regulatory effect of CRIT on the alternative pathway are 
summarized in Section III. In view of the fact that the classical and alternative 
complement pathways have many functional and structural similarities, the regulatory 
effect of CRIT on the alternative pathway was further investigated. In this study, as 11 
amino acid peptide (CRIT-H17) derived from the C-terminal part of CRIT-ed1 was used, 
as it was found to be a potent inhibitor of the classical pathway. The data presented 
indicates that CRIT-H17 also functions as a regulator of the alternative pathway. Besides 
binding C2, CRIT-H17 was shown to bind factor B and its two fragments, Ba and Bb, 
and C3b but not factor D. For this, interacting proteins were stabilized with a cross-
linking agent and complexes detected by immunoblots. CRIT-H17 bound to FB, possibly 
at the junction of Ba and Bb near the factor D cleavage site, and blocked the factor D-
mediated cleavage of FB. Unlike DAF, CRIT-H17 had no decay accelerating activity on 
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the C3bBb complex. Additional experiments showed that CRIT-H17 partially inhibited 
the factor I-mediated cleavage of C3b in the presence of factor H or CR1. These data 
indicate that the regulatory role of CRIT-H17 in the alternative pathway is complex, 
probably related to its dual binding to factor B and C3b.   
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GENERAL INTRODUCTION 
 
Complement System 
Complement is the name given to a triggered enzyme system of over 30 glycoproteins 
found in blood plasma and on body cell membranes [1]. Many of them are labeled with 
the letter C followed by a digit, with the further suffixes indicating the cleavage products 
of proteolysis, and with the letter i representing an inactive derivative. The complement 
system is part of the immune system and is a crucial component of innate immunity as 
well as adaptive immunity [2, 3], and mediates acute inflammatory and cytolytic 
reactions. It plays an important role in host defense and in the elimination of invading 
foreign pathogens. Three separate pathways can activate the complement cascade: 
classical pathway (CP), alternative pathway (AP), and mannose-binding lectin pathway 
(MBL-P), and a serial of host proteins which regulate the complement activation (Figure 
1). Each pathway responds to different activators and activates the complement system in 
a sequential manner but all three pathways converge in the assembly of the C3 convertase 
and end in the formation of C5b-9, known as the membrane attack complex (MAC).  
 
The CP is normally activated by antibody-antigen complexes on the pathogen surface, 
and also acute phase protein (CRP) and is considered predominantly to be an effector of 
the adaptive immune response, whereas the AP and MBL-P are activated directly by 
pathogen surface components and are considered effectors of the innate immune 
response.  
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Figure 1  Complement pathways activation and the regulation of host proteins 
The classical (A), alternative (B) and lectin (C) pathways of complement activation are 
illustrated. Complement activation results in the initiation of the terminal complement 
pathway (D), leading to the formation of membrane attack complexes. Host proteins that 
regulate the different steps of complement activation are indicated in blue [4]. 
C1 inhibitor 
- 
 9
The CP of complement is activated by the formation of immune complexes that bind C1 
and allow a conformational change to occur in the C1 macromolecular complex so that 
C1r and C1s are cleaved. Activated C1s then cleaves C4 with formation of a major 
fragment C4b, which binds to native C2 in the presence of Mg2+ [5]. In turn, C1s cleaves 
C2 into C2a and C2b, with the larger fragment C2a, remaining attached to C4b. When 
bound to C4b, C2a is a newly formed enzyme capable of cleaving C3. C4bC2a is the CP 
C3 convertase [6]. 
 
The MBL-P is initiated by binding of mannose-binding lectin (MBL) specifically to 
mannose residues and to certain other sugar residues on the surface of bacteria, yeast, 
parasitic protozoa and viruses [7]. The concentration of MBL in normal plasma is very 
low and its production by liver is increased during the acute-phase reaction of the innate 
immune response. MBL is a collectin (C-type lectin with a collagen-like domain) which 
is similar to C1q. MBL associated serine protease (MASP)-1 and MASP-2 are similar to 
C1r and C1s in the CP, respectively [8]. Like C1s, MASP-2 can cleave C4 and leads to 
formation of MBL-P derived C3 convertase. MBL-P has structural and functional 
similarities to the CP. Besides the initiating factors, these two complement pathways are 
identical.   
 
The activation of the AP is antibody-independent and generates a distinct C3 convertase, 
C3bBb. The AP is a self amplifying pathway and is important in the clearance and 
recognition of pathogens in the absence of antibodies. The activation of the AP is mainly 
initiated by the spontaneous hydrolysis of the internal thioester bond in plasma C3 to 
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form C3(H2O), which has an altered conformation allowing the binding of factor B (FB) 
[9, 10]. The first step in the AP activation is the nucleophilic attack on the internal 
thioester bond in C3b by an amine or hydroxyl group on the pathogen surfaces, followed 
by the binding of FB to form the C3bB complex [11]. Binding of C3b to FB induces a 
conformational change in FB, which in turn becomes susceptible to the cleavage by 
factor D (FD). The FD-mediated cleavage of FB is the rate-limiting step for generating 
the AP C3 convertase, C3bBb.  
 
Regulation of Complement Activation 
Complement activation is an important but a potentially dangerous system. Inappropriate 
activation of the complement cascades is known to play a key role in various pathological 
conditions. Thus, there are several complement regulatory proteins that protect host cell 
from the potentially destructive effect of complement activation. Most of these proteins 
belong to the regulators of complement activation (RCA) gene family, which are encoded 
in the gene cluster on the long arm of chromosome one [12]. There is one common 
structural motif among the RCA gene family termed the short consensus repeat (SCR), 
which comprises the majority of the molecule and shares approximately 20-40 % 
homology to each other. The RCA proteins interact with C3b and either prevent the 
formation or promote a rapid irreversible dissociation of complement convertases. The 
RCA proteins, decay accelerating factor (DAF), factor H (FH) and complement receptor 
1 (CR1) are responsible for the dissociation of complement C3 convertases and 
membrane cofactor protein (MCP), FH and CR1 act as cofactors in the factor I (FI)-
mediated cleavage of  C3b. 
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Besides the RCA proteins, there are several complement inhibitors developed, including 
recombinant forms of naturally occurring inhibitors, monoclonal antibodies to 
complement components, serine protease inhibitors and analogues of anaphylatoxins [13, 
14]. The search for complement inhibitors continues and aims at the discovery of one or a 
few specific and potent complement inhibitors for clinical use. Table 1 shows various 
potential complement inhibitors, which may be available to the critical care physician.  
 
Table 1  Potential complement inhibitors 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Type of inhibitor Target Reference 
Peptides; monoclonal antibody C1q [15] 
Anti-MBL monoclonal antibody MBL [16, 17] 
C1-inhibitor CP; AP; MBL-P [18, 19] 
Anti-FD monoclonal antibody FD (AP) [20] 
Anti-FB monoclonal antibody FB (AP) [21] 
Soluble CR1 C3 and C5 convertases [22] 
Compstatin C3 [23, 24] 
Pexelizumab (monoclonal antibody) C5 [25] 
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Complement C2 Receptor Inhibitor Trispanning, CRIT 
Schistosomiasis (or bilharzias) is a human disease caused by infection from parasitic 
trematodes of the genus Schistosoma, and is the major source of morbidity and mortality 
for developing countries in Africa, South America, the Caribbean, the Middle East and 
Asia. Parasites use various strategies to evade the complement system. In 1999, a novel 
protein, Sh-TOR (Schistosoma trispanning orphan receptor) was isolated in the blood-
dwelling Schistosoma parasite [26], which was mainly localized on the parasite surface 
with unknown function. The membrane topology of Sh-TOR was predicted by computer 
analysis (PHDhtm) [27] (Figure 2). A 27 amino acids synthetic peptide was made 
corresponding to the first extracellular domain (Sh-TOR-ed1). By affinity 
chromatography using a column of epoxy-activated Sepharose 6B covalently coupled 
with Sh-TOR-ed1, one protein in normal human serum was pulled down. By 
immunoblotting and N-terminal sequencing, this protein was confirmed as complement 
C2 protein [28]. In a hemolytic assay, Sh-TOR-ed1 could block the CP of complement 
activation. These data support that the Sh-TOR-ed1 region possesses a C2 binding site 
and that it functions as a complement inhibitor in the CP. Henceforth, Sh-TOR was re-
named complement C2 receptor inhibitor trispanning (CRIT). A model of CRIT-
mediated inhibition of CP C3 convertase formation was proposed (Figure 3). Expression 
of CRIT on the parasite surface acts a decoy C2 binding receptor to protect the parasite 
from CP-mediated complement attack by competing with C4 for the binding of C2.   
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Figure 2  Schematic representation showing predicted membrane topology of CRIT  
 
CRIT is a three transmenbrane receptor with two extracellular and two intracellular 
domains. An 11 amino acid peptide (CRIT-H17) is derived from the C-terminal region of 
CRIT-ed1, which is highlighted in blue. Some predicted functional motifs in the id2 are 
also highlighted [28]. 
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Figure 3  Model of CRIT-mediated inhibition of CP C3 convertase formation on 
parasite surface. 
 
Antibody (in yellow) binds to the parasite, via some surface molecule, thus fixing C1q 
and associated C1s. C4b binds via a thioester bond to the surface and then associates with 
C2, which is cleaved by C1s to produce the CP C3 convertase, C4b2a. CRIT expressed 
on the parasite surface is able to compete with surface-bound C4b for C2 in the host 
serum, thereby reducing the extent of C3 convertase formation. As the C2 in the C2-
CRIT complex cannot be cleaved by C1s, it is unable to function as a CP C3-like 
convertase [29]. 
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Objectives 
A proper control of complement activation is extremely important in many complement-
mediated diseases. A potentially new and advancing area of therapeutics that may hold 
promise for the critically ill is inhibition of the complement system. Thus, the design or 
discovery of new potent complement inhibitor(s) would be valuable in the future for 
critical care medicine.  
 
CRIT is a novel complement inhibitor of the CP which is presently being biochemically 
and functionally studied. However, as a prerequisite, it’s necessary to check whether 
CRIT also expresses in other organisms, apart from parasites. In addition, to better 
understand its functional role, the cellular and tissue distribution of CRIT must be 
determined. To address these questions, the cloning of CRIT in rat, cod and human were 
performed. For the cell and tissue distribution of CRIT, total protein extracts of various 
cell lines and tissues were prepared for the Western blotting probed with anti-CRIT 
antibody. Also, fresh surgical tissues or tissue microarrays were used for the 
immunohistochemistry. 
 
To dissect out more precisely the CRIT binding region on C2, vWFA domain of C2 was 
cloned and the recombinant C2 vWFA protein was expressed and purified. The 
recombinant C2 vWFA protein was also useful for studying the interaction between C2 
and C4. Besides the protein-protein interaction studies, it could be used for future 
structural studies by X-ray crystallography. With all this empirical data, the mechanism 
of CRIT-mediated inhibition of the CP activation will be defined more clearly.  
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Besides the inhibitory effect on the CP activation, it was important to test whether CRIT 
also possesses any regulatory effect on the related AP. The ultimate goal of this study is 
to fully understand the regulatory role of CRIT in the complement system.  
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ABSTRACT 
The complement system presents a powerful defense against infection and is tightly 
regulated to prevent damage to self by functionally equivalent soluble and membrane 
regulators. We describe complement C2 receptor inhibitor trispanning (CRIT), a novel 
human complement regulatory receptor, expressed on hemopoietic cells and a wide range 
of tissues throughout the body. CRIT is present in human parasites through horizontal 
transmission. Serum complement component C2 binds to the N-terminal extracellular 
domain 1 of CRIT, which, in peptide form, blocks C3 convertase formation and 
complement-mediated inflammation. Unlike C1 inhibitor, which inhibits the cleavage of 
C4 and C2, CRIT only blocks C2 cleavage but, in so doing, shares with C1 inhibitor the 
same functional effect, of preventing classical pathway C3 convertase formation. 
Antibody blockage of cellular CRIT reduces inhibition of cytolysis, indicating that CRIT 
is a novel complement regulator protecting autologous cells. 
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INTRODUCTION 
An overview of known human membrane regulators of complement activation (RCA) [1, 
2] indicates that cell membranes have no equivalent to C1 inhibitor (C1-INH), a serine 
protease inhibitor that regulates the classical pathway (CP). C1-INH also inhibits the 
mannan-binding lectin pathway by inhibiting mannan-binding lectin-associated serine 
proteases [3]. Schistosoma complement C2 receptor inhibitor trispanning (CRIT; 
formerly, trispanning orphan receptor) like C1-INH inhibits C1s-mediated cleavage of 
C2, so preventing formation of the CP C3 convertase, C4b2a. However, their mode of 
action differs. C1-INH regulates the CP at the C1 level by binding stoichiometrically to 
the active sites on both C1r and C1s [4]. CRIT binds to C2 in a manner that inhibits its 
C1s-mediated cleavage. There is no enzymatic inhibition and CRIT is presumably 
protecting the C1s cleavage site on C2. 
 Homologs of complement regulator proteins are found on parasites such as 
trypanosomes and schistosomes living in the mammalian host vasculature [5]. 
Trypanosomes are protected by decay-accelerating factor (DAF) and CD59 homologs 
with decay-accelerating activity either for the alternative pathway (AP) [6] or else for 
both the CP and AP convertases [7], whereas schistosomes adsorb host DAF from 
erythrocytes [8]. Schistosoma CRIT having a putative complement-protecting function in 
schistosomes is found on the surface of the Schistosoma parasite [9]. We have now 
cloned a CRIT homolog from the Trypanosoma parasite, and found close homologs in 
human, rat, and cod.  
 We found human (Hu)-CRIT to be expressed on a wide range of tissues as well as 
on hemopoietic cells. We suggest that this novel receptor with three N-terminal 
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transmembrane (TM) domains represents a novel family of receptors and present several 
lines of evidence supporting CRIT as receptor for C2. The complement regulatory 
function of CRIT was suggested previously [10, 11] by using CRIT extracellular domain 
1 (ed1) and its 11 amino acid C terminus (CRIT-H17) to inhibit CP-mediated hemolysis 
in the presence of normal human serum (NHS). We have now shown that, by blocking 
CRIT through preincubation with anti-CRIT-ed1, two CRIT-expressing human myeloid 
cell lines as well as monocytes, can be deprotected, resulting in increased susceptibility to 
Ab-dependent complement lysis in vitro. When C2 binds to CRIT on the cell surface, it 
does not form a variant-C3 convertase, because C2 cannot be cleaved by C1s. Having 
found this previously with synthetic CRIT-ed1 peptide, we now show this to be the case 
with native membrane-bound CRIT. 
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EXPERIMENTAL 
Antibodies and peptides 
Affinity-purified polyclonal  anti-CRIT-ed1 and anti-C2 antibodies were described before 
[10]. A rabbit polyclonal antibody against Schistosoma hematobium (Sh)-CRIT-ed2 
(NH2-SSTSDIRLVIHTKTGPIYIKST-CO2H (two conservative amino acid changes 
relative to human CRIT-ed2)) was made and affinity purified as described for anti-CRIT-
ed1. Anti-CRIT-intracellular domain 2 (id2) mouse polyclonal antibody was obtained by 
a standard immunization of mice with the synthetic peptide (NH2-
KYEDILKIPTNAYAC-CO2H) based on K195-A208 of the cytoplasmic tail of human 
CRIT, coupled through a C-terminal cysteine to KLH. HRP-conjugated secondary 
antibodies were obtained from Bio-Rad. All synthetic peptides were synthesized as 
described before [10]. The sequences were as follows: ed1 (NH2-
MSPSLVSDTQKHERGSHEVKIKHFSPY-CO2H); ed2 (see above); H17 (NH2-
HEVKIKHFSPY-CO2H); H17S (NH2-EKFYHIHSKPY-CO2H); C4β212–232              
(NH2-FEVKKYVLPNFEVKITPGKPYCO2H); and C4βS (NH2-
FYFNEPVEPKVLPKGVKYTKI-CO2H).  
 
Biotinylation, FITC labeling, and radioiodination od C2 
C2 (50 µg) was biotinylated by using NHS-LC-biotin (Pierce) according to previously 
described methods [10], but using a lower biotin-to-protein ratio of 50 µg of biotin per 
milligram of protein. After dialysis against PBS or PBS containing Mg2+ (1 mM), the 
protein was assayed. For FITC labeling, C2 (10 µg) was incubated with FITC (Sigma-
Aldrich) (6 µl of 0.1 mg/ml) and 1 ml of carbonate buffer at room temperature for 2 h in 
 26
the dark, followed by extensive dialysis against PBS. Radioiodination of C2 was 
conducted according to a standard protocol [12]. Essentially, 100 µg of protein in 0.5 ml 
was added to 100 µg of IodoGen (Pierce). Iodination was conducted by adding 1 mCi of 
Na125I (Amersham Biosciences). Unincorporated iodine was separated from iodinated C2 
using a PD-10 gel filtration column (Amersham Biosciences) presaturated with 5 mg of 
BSA. The specific activity of 125I-labeled C2 was 8 x 104 cpm/mg. 
 
Human cells and cell lines 
Lymphocytes were obtained from heparinized human blood diluted 1/1 with RPMI 1640 
using Histopaque 1077 (Sigma-Aldrich). Erythrocytes and platelets were isolated 
according to a standard protocol [13]. The lymphocytes were washed and resuspended in 
RPMI 1640. Erythrocytes were recovered, and the pellet was washed with PBS. 
Monocytes were obtained from heparinized blood buffy coat by density gradient 
centrifugation using Histopaque-1077 (Sigma-Aldrich). Monocytes were purified by 
adherence separation [14]. Purified monocytes (2 x 105 cells/ml) were dispensed in 100 µl 
aliquots into the wells of a 96-well microtiter plate and stimulated, if necessary, with     
10 U/ml final concentration of human IFN-  (Sigma-Aldrich) and incubated overnight at 
37°C in 5% CO2. To remove the fibroblasts that proliferate on addition of IFN-γ, the 
monocytes were washed three times with RPMI 1640. The human carcinoma cell lines, 
Jurkat, Raji, THP-1, U937, ECV-304, HeLaS3, HS1, MRC5, T47D, and rat cell line, 
C58(NT) (all American Type Culture Collection) were maintained in RPMI 1640 
medium with 10% FCS, glutamine (2 mM), sodium pyruvate (1 mM), penicillin              
(100 U/ml), and streptomycin (100 µg/ml) at 37°C and 5% CO2.  
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SDS-PAGE, Western and ligand (Far Western) blotting 
Protein assays by dye binding using a Bio-Rad protein assay kit were conducted to ensure 
even loadings for SDS-PAGE. SDS-PAGE and immunoblotting analysis of proteins was 
conducted as described before [10]. Reduced samples (with 20 or 50 mM DTT) and 
nonreduced samples were prepared in SDS-PAGE loading buffer. Where necessary in 
experiments to study the covalent oligomerization of CRIT, cell lysis buffer included     
10 mM iodoacetamide. For ligand blotting, the protein to be used as probe (usually C2) 
was biotinylated and detected as described above. For preincubation of biotinylated C2 
(C2bio) with peptides, before probing of a blot, a 10,000 M excess of peptide over C2bio 
was added at 4 °C for 2 h. 
 Tissue extraction for Western analysis was conducted by homogenizing 50 mg of 
tissue in a Dounce homogenizer in 150 µl of RIPA (1% Nonidet P-40, 0.5% sodium 
deoxycholate, and 0.1% SDS in PBS) in the presence of protease inhibitors. After 
centrifugation (14,000 rpm for 10 min), the supernatant was respun as above.  
 For lysates of mammalian cells, cells (typically 30 x 106) were washed twice in 
PBS and resuspended in 0.75 ml of lysis buffer (PBS with 1% (v/v) Nonidet P-40 and      
5 mM EDTA (pH 8)). After adding protease inhibitors (0.2 mM PMSF, 4 mM 
aminoethylbenzenesulfonylfluoride (Pefabloc), 1 mM NaF, 5 µg/ml aprotinin, 4 mM 
benzamidine) (all Sigma-Aldrich), the cells were mixed gently and incubated on ice for 
10 min. After low-speed centrifugation (250 g; 5 min), the supernatant was respun 
(25,000 g; 25 min), and the supernatant was aliquoted and stored (–80°C).  
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 CRIT expression in Escherichia coli was induced with isopropyl-D-
thiogalactopyranoside for 1 h. After harvesting, the bacteria were resuspended in 1/10 the 
original volume of buffer (20 mM Tris-HCl (pH 8.0), 500 mM NaCl, 2 mM EGTA, 
protease inhibitor mixture as for mammalian cell lysate) and lysed with 0.1 mg/ml 
lysozyme, 0.1% Triton X-100, 10 mM MgCl2, 50 µg/ml DNase, and 20 µg/ml RNase for 
60 min at room temperature. Cell lysates were centrifuged (25,000 g for 30 min), and 
supernatants were used freshly.  
 
Immunohistochemistry 
Fresh surgical tissue (kidney and testis) was fixed in 10% neutral buffered formalin. 
Tissue was embedded in paraffin, and 4- to 5-µm sections were cut. Tissue for 
microarrays (BioCat) was similarly prepared. Blocking of endogenous peroxidase was 
conducted with 0.3% H2O2 in methanol for 30 min followed by three 5-min washes in 
distilled water and then one wash in PBS. Tissues were digested with 0.05% proteinase K 
in PBS for 2 min and then washed in PBS. Blocking of nonspecific staining was 
performed by incubating for 20 min in normal horse serum, excess serum then being 
blotted off the sections. The primary antibody was anti-CRIT-ed2 (1/100) incubated 
either overnight at 4 °C or for 1 h at room temperature. For detection, the liquid 
diaminobenzidine substrate-chromogen system (DakoCytomation) was used according to 
the manufacturer’s instructions. Counterstaining was by hematoxylin Mayer, and 
dehydration by using decreasing alcohol concentrations. Finally, stained sections were 
mounted with permanent mounting medium (Eukitt/Fluka Chemical). 
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Immunohistological examination was performed using a Zeiss Axiophot microscope as 
described before [11].  
 
Hemolytic assay 
Essentially, in the hemolytic assay performed, the increasing concentration of CRIT-ed1 
being added to NHS competes with C4b for binding to C2. The effect of this competition 
is measured in this case by the decreased CP C3 convertase assembly and resulting 
decrease of percent hemolysis. This standard procedure has been described previously 
[10]. 
 
Complement-dependent cytotoxicity on CRIT-expressing cells 
Cells (0.25 x 106) were incubated with 100 µl of anti-human lymphocyte serum (1/30) or 
rabbit prebleed/normal rabbit IgG as a control followed by incubation with anti-CRIT-
ed1. After 1 h at 4°C and two washes in isotonic veronal buffered saline with divalent 
cations (GVB2+) [15], 100 µl of 10% NHS in GVB2+ was added for 30 min at 37°C. The 
percent lysis was determined as the percentage of cells permeable to trypan blue.  
 
Flow cytometry 
To detect the binding of C2 to the Jurkat cell surface, the C2 was biotinylated as 
described above. Cells were treated according to the manufacturer’s instructions, for        
5 min at room temperature, with an avidin/biotin blocking reagent (Vector Laboratories). 
Cells were then washed in RPMI 1640 (containing 1% BSA and 0.01% sodium azide), 
resuspended at a concentration of 1 x 106 cells/ml, and incubated on ice for 30 min with 
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50 µl of C2bio (2.75 µg/ml) made up to 100 µl with FACS buffer (1x PBS, 1% BSA, 
0.02% sodium azide). After washes and incubation with 5-µl per reaction streptavidin-PE, 
the cells were fixed with 1% paraformaldehyde for 30 min at room temperature and 
analyzed on a FACScan flow cytometer (BD Biosciences). CellQuest software was used 
for data acquisition and analysis. A total of 10,000 events was analyzed. FITC-labeled C2 
(25 µl of 10 µg/ml) was similarly incubated with 1.5 x 106 Jurkat cells. 
 To examine CRIT expression on the Jurkat cell surface, 1 x 106 cells incubated 
with avidin/biotin blocking reagent, as above, were treated as for labeling with C2bio but 
instead with biotinylated anti-CRIT-ed1 (20 µl of 50 µg/ml).  
 
ELISA 
To investigate the C2 binding to CRIT-ed1 or C4b, first CRIT-ed1 peptide (0.5 µg/well) 
or C4b (2 µg/well) in carbonate buffer (pH 9.6) (with or without 5 mM MgCl2) were 
coated on the plate (overnight at 4°C). After washing in PBS (with 0.05% Tween 20) and 
blocking with 200 µl of PBS (containing 2% BSA), increasing amounts of C2bio (with or 
without 1 mM Mg2+) were added. To see whether CRIT-ed1 can block C2-C4b binding in 
this system, C4b in carbonate buffer was coated on the plate and incubated with C2bio 
(150 ng) in the presence or absence of 1.2 µM ed1 (300 ng) in a final volume of 100 µl. 
Finally, the procedure to detect C2bio binding in our ELISA requiring incubation with 
streptavidin-HRP (1/2500) followed by development with o-phenylenediamine was 
essentially as described before [16]. A490 was measured using a microplate reader 
(spectroMAX 190; Molecular Devices). 
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 Apparent dissociation constants (KD(app)) were calculated using nonlinear 
regression, which was performed by plotting A490 against the concentration of C2 (rather 
than concentration of bound C2 against concentration of free C2 as required for Scatchard 
analysis and KD calculations) and fitting with the one-binding class model (a better fit 
than the two-binding class model) using the GraphPad Prism software (GraphPad 
Software).  
 
DNA isolation and southern blotting 
Rat genomic DNA was purchased (Stratagene). Human genomic DNA for Southern 
blotting was prepared from 500 µl of packed Jurkat cells [17]. Southern blotting [17] 
using the full-length Sh-CRIT cDNA as a probe was conducted at low stringency by 
incubating at 45°C for 16 h, followed by two washes with 3x SSC and 0.1% SDS at room 
temperature, rinsing in 2x SSC. For higher stringency, blots were incubated at 65°C and 
then washed with 1x SSC and 0.1% SDS at 65°C. Blots were exposed to x-ray film with 
an intensifying screen for 48 h. 
 
Cloning of CRIT homologs and in vitro transcription/translation 
A rat homolog of Sh-CRIT was obtained by PCR from rat genomic DNA, using 
degenerate oligonucleotides based on the Sh-CRIT N-terminal and C-terminal nucleotide 
sequence and, where possible, based on a rat codon usage. The primers were as follows: 
RaF (sense), 5'-CGCGATGTC(C/T)CC(A/C/G/T)I(C/G)ICTIGTITC-3'; and RaR 
(antisense), 5'-GCGTTA(G/A)CAAGAIGA(C/G)TG(A/C/G/T)GC(A/G)TT-3'. The PCR 
was conducted at 94°C (30 s), 55°C (60 s), and 72°C (60 s) for 35 cycles. The purified 
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product (using GeneClean (Bio 101)) was then cloned into pGEM-T (Promega), 
according to the manufacturer’s instructions, and fully sequenced in both strands. Human 
genomic DNA was extracted from whole blood using a blood and cell culture DNA mini-
kit (Qiagen), and human testis and pancreas cDNA was purchased from Ambion. Based 
on the sequence alignment of Schistosoma and rat CRIT, oligonucleotides were designed 
with the introduction of a HindIII restriction site at the 5'-end and a KpnI restriction site at 
the 3'-end to enable subcloning into the pcDNA3.1 vector in the correct orientation (HuF 
(sense), 5'-CGAAGCTTATGTCTCCAAGTCTAGTG3'; and HuR (antisense), 5'-
CGGGTACCTTAGCAAGAGAGTGAGC-3'). Pfu ultra high-fidelity DNA polymerase 
(Stratagene) was used, and the amplified PCR product was digested with HindIII and 
KpnI, and ligated into the pcDNA3.1 vector precut with the same enzymes. The ligation 
was transformed into DH5  competent cells [17]. In vitro transcription/translation from 
the pcDNA3.1-HuCRIT template was conducted using the TNT-coupled reticulocyte 
lysate system (Promega) according to the manufacturer’s instructions. The trypanosome 
and cod homologs were obtained similarly by PCR using oligonucleotides based on the 
Sh-CRIT sequence. 
 
DNA sequencing 
All sequencing was conducted on both strands of the pGEM-T clones using an ABI Prism 
BigDye terminators, version 3.0, cycle sequencing kit and detected on an ABI 3100 
Avant Genetic Analyzer, automated DNA sequencer, according to the manufacturer’s 
protocols (Applied Biosystems). Vector-specific primers SP6 and T7 were used, as well 
as primers based on the established insert sequence.  
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Assay for cleavage of C2 by C1s 
This was essentially conducted as described previously [10]. To test for the effect of 
CRIT as expressed on the Jurkat cell surface (5 x 103 cells) as well as the CRIT-ed1 
synthetic peptide (105 µM), on C1s cleavage of C2, they were preincubated with C2       
(2 µg) in 20 mM Tris at 20°C for 30 min. Then, 0.2 µg of C1s was added and incubated 
for 1 h at 37°C before analysis by immunoblotting. 
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RESULTS 
Human and parasite CRIT 
CRIT is found on the larval and adult worm stage of the Schistosoma parasite [9]. Under 
the previous designation of "trispanning orphan receptor," it has also been found recently 
on schistosome eggs [18]. Schistosomes live in veins near the urinary bladder or intestines 
of the host and the CRIT receptor for C2 is able to limit CP C3 convertase formation on 
the parasite surface [10, 19-21]. Southern blotting of human genomic DNA under low 
stringency conditions, using the Sh-CRIT open reading frame (ORF) as a probe, revealed 
a Hu-CRIT homolog (Figure 1A). It was also found that the antibody against the N-
terminal extracellular domain, ed1, of Sh-CRIT recognized a 32-kDa protein in various 
human cells and tissues (described below). 
 The partial sequence of the CRIT homolog in Gadus morhua (Cod-CRIT), and 
full-length sequences of CRIT in Trypanosoma cruzi (Tc)-CRIT, rat (Ra)-CRIT, and Hu-
CRIT were obtained by PCR, the latter from testis and pancreas cDNA. Alignment at the 
amino acid level (Figure 1B) reveals near identical TM domains and ligand-binding ed1 
in all species, the latter accounting for the cross-immunoreactivity, between schistosomes 
and humans in ed1. The high interspecies homology at 82% between full-length Hu- and 
Ra-CRIT also occurs in the G protein-coupled receptor (GPCR) family which can show 
85–98% identity between species [22]. At the nucleotide level, as shown in the 
phylogenetic tree in Figure 1C, the parasite cluster (Sh-CRIT and Tc-CRIT) is as closely 
related to Hu-CRIT as rat, suggesting that these human parasites acquired the CRIT gene 
from their host. The appropriation of host genes by parasites accounts for the many genes 
with high degrees of identity  between parasite (especially schistosome) and host [23, 24],  
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Figure 1  CRIT family genes   
 
(A) Southern blot of human genomic DNA digested with: lane 1, EcoRI, and lane 2, PstI, 
probed with Sh-CRIT full-length cDNA under low and high stringency conditions, 
respectively. (B) Amino acid sequence alignment of CRIT from human (Hu), rat (Ra), T. 
cruzi (Tc), S. hematobium (Sh), and cod. Amino acid identity or similarity is indicated by 
black or gray shading, respectively. The three TM domains are indicated by a bar above 
the sequence. (C) Unrooted phylogenetic tree based on analysis of nucleotides 1–846 of 
Hu-CRIT cDNA sequence with other CRIT cDNAs, using a topological algorithm 
(European Molecular Biology Laboratory-European Bioinformatics Institute Molecular 
Biology Server). Length of line segments, in brackets, is indicative of evolutionary 
distance. 
A 
B 
C 
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and such molecular mimicry in which host proteins are expressed by parasites helps 
disguise the parasite as "self" in terms of the host immune system. We found the 
nucleotide sequence of the Hu-CRIT cDNA to be identical with that of the genomic 
sequence, implying that the ORF of Hu-CRIT is encoded by a single exon, although we 
cannot yet rule out an intron in the untranslated regions. In this study, we present the Hu-
CRIT gene structure only as the predicted ORF based on that of Schistosoma CRIT, thus 
excluding 5' and 3' noncoding regions and other structures such as promoters and 
transcription regulatory elements. The presence of a CRIT gene in cod of which we 
present a partial sequence in Figure 1B, indicates that CRIT genes may have evolved from 
a common ancestral gene, at least present in the earliest teleosts.  
 
CRIT membrane topology and sequence motifs 
Fig. 1D shows how, for five of six topology algorithms, Hu-CRIT, representative of the 
other CRIT sequences, is expected to lie in the membrane. Empirical evidence for the 
internal/external orientation of CRIT has been described before [9] and is supported by 
the fluorescence staining of CRIT-positive cells incubated with anti-CRIT-ed1 (Figure 
2A). The majority of substitutions between the species occur within the first 60 residues 
of the 161-residue cytoplasmic tail, id2, proximal to the third TM domain. Within the 
remainder of the cytoplasmic tail, as illustrated in Figure 1D, and shared by parasite and 
mammalian sequences, are three predicted tyrosine-based YXXØ endocytosis motifs 
(where X is any amino acid and Ø is a strongly hydrophobic amino acid), two di-leucine 
endocytosis  motifs, and,  illustrated  schematically  in Figure 1D, an amphipathic α-helix  
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Figure 1D  Membrane topology 
Schematic of representative Hu-CRIT, showing membrane topology and important 
sequence motifs, common to all sequences presented, including, in the cytoplasmic tail, 
three Tyr-XX-Ile/Leu endocytosis motifs, the third lying within an amphipathic helix (in 
which hydrophobic residues are within shaded circles), as well as two di-leucine 
endocytosis motifs and a serine/threonine rich region. The extracellular domains (ed1 and 
ed2) and intracellular domains (id1 and id2) are also indicated. The region to which the 
anti-CRIT-id2 Ab was designed is illustrated. 
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(putative sorting signal  toward  degradation) [25]. Also within the cytoplasmic   tail, 
there is a consensus binding motif for the Src homology 2 domain of the Src family 
cytoplasmic tyrosine kinases [26], in particular, Fyn, Fps/Fes, and Syk, as well as 
consensus phosphorylation sites for various tyrosine kinases. 
 
CRIT forms covalently linked dimmers 
Having first detected CRIT receptor by flow cytometry on the surface of Jurkat cells 
(Figure 2A), we found, by immunoblotting of a cell lysate, that CRIT exists as a dimer 
under nonreducing conditions (B). Comparison of a nonreduced Jurkat extract (NR,      
lane 1) with a reduced extract (R, lane 2) shows, under reducing conditions, the 
disappearance of the dimeric form and a slight increase in intensity (which was frequently 
more prominent) of the monomeric form. The presence of the sulfhydryl trapping agent 
iodoacetamide (10 mM) in the cell lysis buffer did not prevent the appearance of the 
covalently linked dimeric CRIT (not shown), meaning that disulfides were not formed 
artifactually as a result of prevailing non-denaturing and oxidizing conditions during cell 
lysis. At this stage, we cannot categorically say whether homo- or heterodimerization is 
occurring. However, because dimers occurred in Jurkat cells that do not make C2, 
regardless of whether they were maintained in complete or serum-free medium, it appears 
that the dimerization is constitutive and not dependent on ligand. Furthermore, 
heterodimerization could conceivably occur between CRIT and a molecule other than C2. 
To resolve this, studies are ongoing to cotransfect cells with CRIT possessing different 
tags to see whether (homo-)dimers can be detected with both tag-specific antibodies. If 
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homodimerization is occurring, then disulfide bonds could be formed between any of the 
three cysteines in TM1, one each in TMs 2 and 3 and three in the cytoplasmic tail.  
 
CRIT cellular and issue distribution 
We expressed Hu-CRIT both in E. coli (Figure 2C) and by in vitro transcription 
translation (D) as a ~31- to 32-kDa protein. Full-length CRIT1–280 was also detected in 
Jurkat cell lysates using anti-ed1 or anti-ed2 as well as an antibody, anti-id2, against the 
cytoplasmic tail of CRIT, specifically against a peptide based on the region K195–A208. 
Anti-ed1 also revealed the rat CRIT homolog as a ~31- to 32-kDa protein in the rat T cell 
line, C58 (NT). Comparing CRIT sequences available, the predicted size of human CRIT 
is not dissimilar to CRIT from T. cruzi, S. hematobium/S. mansoni/S. japonicum, or rat. 
Compared with CRIT monomer electrophoresed under nonreducing conditions (Figure 
2D), 1 mM DTT decreased the electrophoretic mobility of CRIT monomer (as viewed on 
an 8% SDS-PAGE gel to maximize the resolution of proteins between 20 and 40 kDa), 
indicating a likely reduction of an intramolecular disulfide bond. 
 Western blotting (Figure 2E) showed expression of CRIT in various human 
hemopoietic cell lines including Jurkat (T lymphocyte), Raji (B lymphocyte), THP-1 
(myeloid), U937 (myeloid), and ECV304 (endothelial), as well as several nonleukocyte 
cells (Table 1) such as T47D (epithelial breast ductal) and weakly on HeLaS3 (epithelial) 
and MRC5 (fibroblast). In addition, CRIT was detected by immunoblotting in human 
platelets, monocytes, dendritic cells, and lymphocytes, but not in erythrocytes, 
neutrophils, nor HS1 (liver fibroblast-like cell line). CRIT was also found (Figure 2E and 
Table I) in testis, tonsil, kidney, thymus, and liver (latter not shown), but not in colon.  
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Figure 2  CRIT cell/tissue distribution and oligomer formation  
 
(A) Recognition of CRIT on Jurkat cell surface by FACS analysis and 
immunofluorescence microscopy (inset). (B) Immunoblot of Jurkat cell lysate run under 
nonreducing (without DTT) and reducing conditions (+50 mM DTT) on a 12% SDS-
PAGE gel shows dimer formation. The signal, which was absent after incubation with 
anti-CRIT-ed1 preabsorbed with ed1 peptide was also absent after incubation with 
preimmune serum (latter not shown). Cell lysates made in the presence of iodoacetamide 
(50 mM) also showed CRIT dimers under nonreducing conditions. (C) Expression in E. 
coli of 32-kDa Hu-CRIT (1–282 aa). (D) CRIT ORF cDNA (nt 1–846) expressed in a 
cell-free in vitro transcription/translation system and resulting protein probed in Western 
blot with anti-CRIT-ed1. Full-length Ra-CRIT1–282, is detected in a rat T cell line, 
C58(NT), with anti-ed1 on an 8% gel and in a human T cell line (Jurkat) lysate, Hu-
CRIT1–280 is detected with several antibodies: CRIT is detected in Jurkat cells with anti-
id2 antibody, against the region K195-A208 of the cytoplasmic tail, as well as anti-ed2. 
CRIT monomer is also detected under reducing conditions with anti-ed1 at a slightly 
lower electrophoretic mobility than the nonreduced monomer. (E) Western blots probed 
with anti-CRIT-ed1 of total protein extracts of various human hemopoietic cell lines and 
human tissues, run under reducing conditions. 
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Table 1  Cell and tissue distribution of Hu-CRIT 
Cell Type / Tissue CRIT 
T47D (epithelial breast ductal carcinoma) + 
MRC5 (fibroblast, passage 31) +/− 
HS1 (liver fibroblast) − 
HeLa S3 (cervix uteri epithelial carcinoma) +/− 
Monocytes + 
Macrophages − 
Lymphocytes + 
Neutrophils − 
Dendritic cells + 
Platelets + 
Erythrocytes − 
Liver + 
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 Localization of CRIT in 38 normal, fresh (biopsy material) human tissues was 
determined by immunohistochemistry (summarized in Figure 3) using anti-CRIT-ed2, 
which unlike anti-CRIT-ed1, worked well in staining of paraffin-embedded sections. We 
were able to establish the following distribution for the CRIT receptor: CRIT was found 
to be strongly to moderately positive in almost all tissues in smooth muscle cells (SMCs) 
and related cells (pericytes) in vessels. According to the literature, complement regulators 
DAF, CD59, membrane cofactor protein (MCP), and Crry are expressed at the mRNA 
level by vascular SMCs in rat [27], whereas C3 and C4 are found in human SMCs [28]. 
Interestingly, CRIT stained strongly in glandular epithelial cells in the endometrium 
(Figure 3A) during the proliferating but not secretory phase. Likewise, MCP, DAF, and 
CD59 are expressed on an endometrial epithelial cell line [29] and, together with 
complement receptor 1 (CR1), expressed in normal endometrial tissue in all phases of the 
menstrual cycle [30]. Other CRIT-positive cells include pancreatic islet cells (Figure 3B) 
(which, according to their percentage and distribution, are suggestively insulin-producing 
cells), cells which also express CD59 and MCP [31]. Keratinocytes in the esophagus 
(which express DAF, MCP, and CD59) [32] also stained positive for CRIT (Figure 3C). 
In the esophagus, SMCs were also clearly CRIT positive (Figure 3D). In the kidney, anti-
CRIT-ed2 showed a strong reaction with podocytes in kidney glomeruli (Figure 3E) (as 
for CR1) [33] as well as endothelia and SMCs of blood vessels (F) but not in fibrocytes. 
However, DAF, MCP, and CD59 are expressed on glomerular epithelial, endothelial, and 
mesangial cells [34]. In the testis (Figure 3G and H), there was a positive reaction of 
scattered  and  partly  elongated cells attached to the basement membrane of the testicular  
tubules, which most likely are  Sertoli cells. CRIT  was also found in the  myoepithelia  of  
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Figure 3  Cellular localization of CRIT by immunohistochemistry in various human 
tissues probed with anti-CRIT-ed2  
 
Proliferating endometrium (A); pancreas (B); esophagus (C and D); kidney (E); 
venules/arterioles in kidney (F); testis (G and H). Scale bars, F and H, 100 µm; A-E and 
G, 50 µm. SS, Stratified spinosum; SG, stratified germinativum; SC stratified corneum; 
SM, smooth muscle; sert, Sertoli cells. Controls that consistently gave no staining (not 
shown) included omission of primary antibody (anti-ed2) as well as primary antibody 
absorbed with ed2 peptide. Identical staining patterns in kidney were obtained from at 
least 10 fresh tissue samples. 
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some exocrine glands (breast) and in stromal cells in breast and prostate gland. Finally, in 
the placenta, there were groups of decidual cells weakly positive for CRIT.  
 
CRIT binds complement C2 
We previously demonstrated C2 binding to Sh-CRIT-ed1 by affinity purification of C2 
from NHS using the Sh-CRIT-ed1 peptide [19]. Furthermore, by using C2 hemolytic 
assays in which limiting amounts of C2 (just sufficient to restore complement activity) 
were added to C2-deficient serum, we showed that preincubation of C2 with CRIT-ed1 
peptide inhibited complement activation [10]. We now confirm the C2 interaction with 
Hu-CRIT by ligand blotting. For this, total protein lysates of Jurkat cells, immunoblotted 
onto nitrocellulose, were probed with C2bio (Figure 4A). C2, like anti-ed1, bound to 
monomeric and dimeric CRIT. C2 still bound when preincubated with either CRIT-ed2 
peptide or CRIT-H17S peptide. However, CRIT-ed1 peptide abrogated C2 binding. 
Identical results were obtained with 125I-labeled ligand. In work to be reported in detail 
elsewhere, we showed that a recombinant von Willebrand factor A (vWFA) domain of 
C2, binds CRIT via ed1, and that this binding can be blocked by prior incubation of 
vWFA with the C2 monoclonal antibody Hyb-5050 [35]. In this study, we show that the 
vWFA domain of C2 expressed and purified from E. coli, binds in vitro-expressed CRIT. 
After stabilizing the protein interaction by cross-linking, both unbound CRIT and CRIT-
vWFA C2 are detected by anti-CRIT-ed1 in Western blots (Figure 4B). The binding of 
biotinylated C2 or FITC-labeled C2 (not shown) to Jurkat cells via Hu-CRIT-ed1 was 
also shown by FACS analysis (Fig. 4C) (and immunofluorescence microscopy). Binding 
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could be eliminated by prior incubation of the cells with anti-CRIT-ed1 blocking 
antobody.  
 The dependence on C2bio concentration for the ELISA signal of C2bio interacting 
with C4b or CRIT-ed1 and that this interaction is a saturable phenomenon are shown in 
the graph of binding data or A490 (y) as a function of ligand concentration (X) (Figure 4D). 
Analysis of the results indicated that the one-binding class model was a better fit than the 
two-binding class model. This dose dependency and saturable binding is also shown in 
the graph inset. Nonlinear regression of the equation describing one-site binding of ligand 
to receptor that follows the law of mass action (y = BmaxX/KD(app) + X ; Equation 1), where 
Bmax is the maximal binding, and KD(app) is the concentration of ligand required to reach 
half-maximal binding) onto the data shown in Figure 4D gave an estimate for KD(app) of 
0.0152 µM for C4b/C2bio. This is in close agreement with the KD estimate of 0.015 µM 
for C4b/C2 by plasmon surface resonance [36] and indicates that the biotinylation of C2 
had not compromised its protein-binding ability. In our study, the KD from a Scatchard 
analysis plot of concentration of C2 bound (vbound) against concentration of free C2, was 
not calculated. 
 Although we have no data for the affinity of C2 for native CRIT, we have been 
able to estimate the affinity for the ligand-binding region, CRIT-ed1 in the form of a 
synthetic peptide. Comparison of data for C2bio binding CRIT-ed1 or C4b (Figure 4D) 
indicates that an ELISA reading for CRIT-ed1/C2bio binding 3-fold lower than for 
C4b/C2bio corresponds to a KD(app) for CRIT-ed1/C2bio (0.022 µM) 2-fold lower than 
between C4b/C2bio (0.0152 µM) (KD of 0.015 µM [36] (Table II). According to our 
estimations, C2 has an equal to 2-fold lower affinity for CRIT than for C4b and therefore 
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could not prevent assembly of the CP C3 convertase but is more likely reducing excessive 
activation on a target. The concentration of C2 (ligand) in plasma is 0.25 µM. This is ~10 
times the average (using two different methods; Table 2) equilibrium dissociation 
constant of C2-CRIT receptor complexes, KD(app) of 0.0235 µM, implying (Equation 1) 
that C2 will occupy 90% of CRIT receptors at equilibrium. 
 Again, maximum blockage of the C4b/C2bio interaction was possible (Figure 4E) 
by preincubation of C2bio with a concentration of ed1 (1.2 µM) 80 times that of the KD 
for C4b/C2 (0.015 µM) and ~51 times the KD for CRIT-ed1/C2 (0.0235 µM). This is in 
agreement with predictions for ligand/receptor associations that the ligand concentration 
needs to be 99 times the KD to occupy 99% of the receptors at equilibrium. C4b/C2bio 
binding could not be inhibited by preincubating C2bio with ed2 (Figure 4E). 
 As an additional test of the binding of C2 to CRIT-ed1, it was possible to inhibit 
the binding of C2 to C4 in the assembly of the CP C3 convertase with increasing 
concentrations of CRIT- or C4-based peptides. Plotting percent inhibition of hemolysis, 
as a measure of the extent of binding of CRIT- or C4-based peptides to C2, resulted in 
Figure 4F. Similar nonlinear regression calculations of the data gave estimates of KD(app) 
for CRIT-ed1/C2 of 0.025 µM and C4β212–232/C2 (where C4β212–232 is the C4β-chain 
peptide described before [10] of 0.011 µM. These data are in good agreement with other 
empirical data summarized in Table II, and are not compromised by the many proteins in 
NHS, because the CRIT-ed1/C2 vs C4b/C2 interactions are highly specific. CRIT-H17 
representing the 11 amino acid C-terminal part of CRIT-ed1 has a 10-fold order of 
magnitude greater affinity for C2 than CRIT-ed1. Interestingly, in preliminary unreported  
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Fifure 4  Complement component C2 binds Hu-CRIT on the cell surface via 
extracellular domain 1 
 
 (A) Ligand blotting showing binding of C2bio to the dimeric and monomeric forms of 
Hu-CRIT in Jurkat cells. Blocking is successful by preincubation of C2 with a 10,000 M 
excess (100 µM) of CRIT-ed1 peptide only. (B) CRIT expressed in an in vitro 
reticulocyte lysate system binds to rC2 (vWFA domain). The proteins are then cross-
linked as described before [10] and detected by immunoblotting (IB) with anti-CRIT-ed1. 
(C) Binding of C2bio to Jurkat cell surface in FACS analysis. Binding is blocked by 
preincubating cells with anti-CRIT-ed1. (D) ELISA for binding of C2bio to C4b or CRIT-
ed1. (E) Blockage of ELISA signal for C4b/C2bio interaction with CRIT-ed1, but not 
CRIT-ed2 peptide. (F) Percent inhibition of hemolysis (as a measure of the extent of 
binding of CRIT- or C4-based peptides to C2) with increasing peptide concentration. 
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Table 2  Dissociation constant (KD(app)) for C2 binding to CRIT-ed1/-H17 and 
C4β212-232/C4ba 
 
 C2-Interacting Protein 
Assay CRIT-ed1 CRIT-H17 C4β212-232 
Hemolytic assay 0.025 0.0033 0.01 
Surface plasmon resonance [36]   0.015 (C4b/C2) (KD) 
ELISA 0.022  0.0152 (C4b/C2) 
 
aMicromolar concentration. Mean of four independent experiments. 
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results before  the study of  Inal and Schifferli  [10],  CRIT-H17  alone, but  not  CRIT-
ed1, gave significant reductions in various parameters of complement-mediated 
inflammation in the reversed passive Arthus reaction in mice [11]. In all current 
experiments, C2 binding to Hu-CRIT-ed1 was not Mg2+ dependent.   
 
CRIT inhibits CP-mediated complement cytolysis 
To ascertain whether CRIT is able to protect cells from complement-mediated attack, 
cells sensitized with antibodies against human lymphocytes (or whole human serum) 
were incubated with increasing concentrations of anti-CRIT antibody, before exposure to 
NHS as a source of complement. A titration was first conducted with increasing NHS 
(Figure 5A) to show that lysis was being achieved with this system and to find a 
convenient serum concentration (chosen to be 10%) to be able to see easily any increase 
in percent lysis of cells. The results (Figure 5B) show a significant increase, from 8% 
lysis without antibody to 28% lysis with 12.5 µg/ml anti-CRIT-ed1 in the promonocytic 
cell line, U937. With the macrophage-like THP-1 cells (Figure 5C), and monocytes (D), 
there were significant increases from 10 and 15% lysis, respectively, to 43 and 52%, 
respectively, with 10 µg/ml. As noted previously, macrophages are negative for CRIT 
(see Table I). Monocytes treated with IFN-γ, thereby expressing lower levels of CRIT, 
showed a nonsignificant increase in cytolysis from ~20% without antibody to 34% with 
10 µg/ml anti-CRIT-ed1. To control for a possible activation of complement through the 
presentation of additionally bound anti-CRIT and so additional Fc by the neutralizing 
anti-CRIT antibody, we incubated cells with increasing anti-CRIT-ed1 but without prior 
sensitization with the complement-fixing anti-lymphocyte serum. Under these conditions 
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shown in Figure 5B and C ( ), there was no increase in cytolysis with increasing anti-
CRIT-ed1 concentration, indicating that the blocking antibody did not activate 
complement.  
 
C2 bound to CRIT is rendered resistant to C1s cleavage 
We and others have shown previously that CRIT-ed1 inhibits the complement-mediated 
lysis of sheep erythrocytes [10, 19-21]. Having also shown that cleavage of C2 by C1s 
was inhibited in the presence of ed1 peptide, we now wanted to see whether this 
inhibition could be provided by native CRIT as found on the surface of Jurkat cells. As 
illustrated in Figure 5E, CRIT-ed1 peptide completely inhibited C1s cleavage of C2. This 
is in contrast to cleavage to C2a and C2b by C1s in the presence of sham peptide (C4βS). 
Interestingly, in the presence of Jurkat cells (and therefore CRIT), there is almost no 
cleavage of C2. When the receptor is blocked with anti-CRIT-ed1, the inhibition by CRIT 
of C1s-mediated cleavage of C2 is lifted. 
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Figure 5  Complement-dependent cytotoxicity is suppressed by CRIT on CRIT-
expressing cells 
 
 (A) Mean effect of increasing NHS on the percent lysis of antibody-sensitized (using 
anti-lymphocyte serum) human U937 and THP-1 carcinoma cells after 37°C incubation 
for 30 min. Effect of increasing anti-CRIT-ed1 on the percent lysis in the presence of 
10% NHS, after 37°C incubation for 30 min, of antibody-sensitized U937 cells (B), THP-
1 cells (C), and IFN-γ-differentiated monocytes (D), vs untreated monocytes. As a 
control both for probable activation of complement by the blocking anti-CRIT-ed1 and 
for showing that CP is being considered, in B and C, the mean effect of increasing anti-
CRIT-ed1 on THP-1 and U937 cells, pretreated with normal rabbit prebleed or rabbit 
IgG, was also detected in the same assay. The results presented are the mean of three 
experiments. (E) Cleavage of C2 (2 µg) by C1s (0.2 µg) in the presence of the following: 
lane 1, 5 x 103 Jurkat cells; lane 2, as for lane 1 but cells preincubated with anti-CRIT-
ed1 (20 µg/ml) for 30 min at 20°C; lane 3, 150 µM CRIT-ed1 peptide; lane 4, 150 µM 
control sham peptide (C4 S) [10]; lane 5, uncut C2; lane 6, C2 cleaved with C1s. 
Throughout, C2 is detected by immunoblotting using anti-C2 antibody [10]. 
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DISCUSSION 
The complement system is a rapidly activated and self-amplifying system that, to avoid 
extensive consumption and self-depletion, requires control at several levels. Interestingly, 
there is often symmetry of function between inhibitors of complement in the fluid phase 
and on cell surfaces [37], although there is an exception: C1-INH is a major regulator of 
C4 and C2 cleavage in the fluid phase, preventing excessive formation of the C3 (C4b2a) 
convertase. 
 Hu-CRIT was cloned from both genomic and cDNA. Thus, although the 5' and 3' 
untranslated regions may yet be found to possess introns, the high level sequence identity 
suggests that the coding region of Hu-CRIT could be coded for within a single exon and 
therefore be intronless, as for example are many GPCR genes. Whether the entire CRIT 
gene is shown to possess introns or not, we have presented evidence that it encodes a 
functional receptor (of a size equivalent to that predicted from the ORF) that has affinity 
for the human complement serum protein, C2. Using an antibody raised against the N-
terminal extracellular domain, CRIT was found on the plasma membrane in a wide 
variety of human cell types. We show that the Schistosoma (and Trypanosoma) parasite 
and its human host share a receptor for C2, and we postulate that they share a 
complement regulatory function. The high sequence homology between the mammalian 
(human and rat)/parasite (Schistosoma and Trypanosoma) and cod CRIT genes is also 
indicative that they may have evolved from a common ancestral gene. 
 CRIT regulates the formation of the CP C3 convertase by reducing the association 
of C2 with C4b. The KD(app) of CRIT-ed1/C2 is of the same order as the KD for C4b/C2 
(0.015 µM) [36] and also CR1 for C3b dimers (0.01–0.02 µM) [38, 39]. Overall, CRIT-
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ed1 appears to compete with C4b for binding to C2 with an apparent moderate affinity, 
but we do not yet know whether CRIT accelerates the decay of the C4b2a convertase. In 
this study, we have found that anti-CRIT-ed1 blockage of the CRIT receptor increases the 
complement-mediated killing of two human myeloid cell lines (U937 and THP-1) and of 
monocytes. However, the relative contribution of CRIT to protecting against complement-
dependent cytotoxicity in the THP-1 cells, for example, cannot be known, because certain 
other complement regulatory proteins are expressed, such as CD59 [40]. Once C2 is 
bound to CRIT (unlike C2 bound to C4b), it cannot be cleaved by C1s to yield C2a and 
C2b and thus no longer partakes in C3 convertase formation. Of the complement 
regulators that control the C3 convertase (C4b2a) and C5 convertase (C4b2a3b), three of 
them, DAF, CR1, and C4BP, compete with C2 for binding to C4b and also bind to C3 or 
C5 convertases, causing C2 dissociation. These proteins are composed mainly or only of 
complement control protein repeats, which contain the C4b (and C3b) binding sites and 
are all encoded by genes in the RCA cluster on chromosome 1q31–32. CRIT, like CD59, 
is another member of the complement control family of proteins that lacks structural 
resemblance to the RCA group of proteins. 
 In humans, CRIT is widely distributed. It is present on many hemopoietic cells, 
but not neutrophils, and notably, like MCP, not on erythrocytes. CRIT is found in many 
tissues, and interestingly, like DAF [41], its expression appears to be hormonally 
regulated during the menstrual cycle. CRIT is also found on endothelial and epithelial 
cells. Besides its complement-regulating function concomitant with its wide distribution 
in the body, we speculate that its particular expression in highly differentiated cell types, 
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such as glomerular podocytes [42], Sertoli cells [43], and keratinocytes [44, 45], could 
suggest additional roles.  
 Complement results in the release of the anaphylatoxins C3a and C5a, which in 
turn bring about the proinflammatory responses of complement, including an increase in 
vascular permeability, mast cell degranulation, and smooth muscle contraction. C5a is 
then able to further increase the proinflammatory response by inducing chemotaxis of 
macrophages and neutrophils and by the activation of neutrophils. These inflammatory 
responses are a natural reaction of host tissue to injury. However, an unregulated 
inflammatory response may injure host tissues and is important in many complement-
mediated diseases [46]. As complement and its activation products, in particular, C5a, can 
aggregate, stimulate, and cause degranulation of neutrophils, any anti-inflammatory 
agents should, in certain diseases, preferably interrupt the complement cascade at an early 
stage. In myocardial infarction, for example, it might be important to block CP and/or 
lectin pathway but leave the AP and lytic pathway intact. By competing with C4b for 
binding to C2, and inhibiting its activation, CRIT prevents the formation of the CP C3 
convertase and is thus an obvious target for diminishing the proinflammatory response of 
unregulated complement activation. A soluble form of CRIT in the form of the CRIT-ed1 
peptide has been shown to inhibit CP-mediated hemolysis by human serum. Indeed, 
recombinant soluble forms of the membrane complement inhibitors have been proven to 
inhibit complement-mediated inflammation [46]. If soluble CRIT in the form of the 
CRIT-ed1 peptide or the smaller CRIT-H17 derivative peptide is not antigenic in humans, 
then it could potentially be used as a therapeutic agent against certain complement-
mediated human diseases. The first promising tests of the in vivo efficacy of CRIT-H17 
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in blocking immune complex-mediated tissue injury in the classical inflammation model, 
the reversed passive Arthus reaction [11], and in Forsman shock [20] should be further 
addressed. 
 It is well documented that conformational changes can occur within the secondary 
structure of a receptor upon reduction [47, 48]. Essentially, reduction of the 
intramolecular disulfide bond(s) of a protein, as we believe occurs with CRIT, results in 
its unfolding from a globular state to a more rod-like conformation, which migrates more 
slowly in an SDS-PAGE gel. Whether CRIT folding or dimerization affects its ability to 
bind ligand, as for example with the TNFR, BAFF-R [49], will be the subject of future 
work. 
 If the dimerization of CRIT occurs through the formation of intermolecular 
disulfide bonds then candidate cysteine residues would be Cys31,40,41 of TM1, Cys69 of 
TM2, Cys110 of TM3, or Cys126,214,280 of the cytoplasmic tail. Disulfide linkages are not 
usually found in the cytoplasm because of the reducing environment there. Because there 
are no cysteines in the extracellular domains, it seems probable that the cysteines in the 
TM domains are involved in dimerization. Disulfide-bonded dimers, mediated through 
TM domains have been reported for some receptors such as CD44 [50] and the insulin 
receptor [51]. Although reducing agents can dissociate receptor homodimers suggesting 
disulfide-bonded dimerization, other intermolecular hydrophobic interactions, between 
TM domains, have been implied, at least for the GPCRs [52]. We previously noted that 
the C2-binding CRIT-H17 motif [F/H]EVKX4/5P, which in the C4β chain occurs 
contiguously, separated by a β-turn, in CRIT, occurs only once, and also speculated that 
CRIT might be found to exist as a dimmer [10]. Our current study has shown Hu-CRIT to 
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form dimers (and that C2 binds to both CRIT monomers and dimers). If these dimers are 
shown to be homodimers, then it is conceivable that two CRIT-H17 motifs (forming part 
of two ed1 regions) could be brought into close proximity for C2 binding, as in the C4β 
chain. Whether dimeric CRIT binds C2 with greater affinity and represents the functional 
form of the receptor we cannot say, but already the work of Oh et al. [20] indicates that a 
recombinant homodimeric CRIT-H17 peptide has an increased binding capacity for C2 
and 5-fold higher anti-complementary activity. 
 In addition to genetic abrogation and mutagenesis experiments in cells, which 
together with structural studies are revealing details of the CRIT-ed1 interaction with C2, 
it is envisaged that CRIT gene knockout experiments will place the relative contribution 
of CRIT toward complement regulation in context with other CP regulators.  
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ABSTRACT 
CRIT (complement C2 receptor inhibitor trispanning) is a newly described 
transmembrane molecule capable of binding C2 via its first extracellular domain (ed1). 
CRIT competes with C4b for the binding of C2. Previous experiments have suggested 
that a major binding site for C2 is located on short almost identical peptide sequences of 
CRIT-ed1 and the β-chain of C4. The C2 domains involved in these bindings, however, 
remain unknown. We cloned the von Willebrand factor-A (vWFA) domain of C2 as it is 
a region likely to be involved in interactions with other proteins, and were able to 
functionally express the 25 kDa human complement C2 vWFA domain (amino acid 224-
437). The recombinant vWFA protein fixed on MagneHis Ni-particles bound C4 in 
normal human serum. The C4α, β and γ chains were separated by SDS-PAGE and 
purified separately by electro-elution. The purified C4 chains were then used in a 
sandwich ELISA, which showed the vWFA to bind C4 only via the C4β-chain. In a 
hemolytic assay, the recombinant vWFA protein inhibited complement activation by the 
classical pathway in a dose dependent manner by competing with native C2 for binding 
to C4b. vWFA bound the ed1 peptide of CRIT as well, and specifically the 11 amino 
acids peptide fragment of ed1 known to interact with whole C2. These findings show that 
the vWFA domain is centrally involved in the C2/CRIT and C2/C4b bindings. The 
cloned vWFA domain will allow us to dissect out the fine interactions between C2 and 
CRIT or C4b. 
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INTRODUCTION 
In general the classical pathway (CP) of complement is activated by the formation of 
immune complexes that bind C1 and allow a conformational change to occur in the C1 
macromolecular complex so that C1r and then C1s are cleaved. Activated C1s then 
cleaves C4 with formation of a major fragment C4b. This fragment is endowed with a 
novel property, which is to bind native C2 in the presence of Mg2+. In turn C1s cleaves 
C2 into C2a and C2b, with the larger fragment, C2a remaining attached to C4b. When 
bound to C4b, C2a is a newly formed enzyme capable of cleaving C3.  C4bC2a is the CP 
C3 convertase. In humans the early activation of the CP is regulated by C1 inhibitor in 
the fluid phase, but until recently no inhibitor preventing the formation of the CP C3 
convertase was known to be present on cell surfaces. Complement C2 receptor inhibitor 
trispanning (CRIT) is a novel human complement inhibitor expressed on hemopoietic 
cells and a wide range of tissues [1]. The denomination trispanning was chosen because 
CRIT has 3 transmembrane domains with one end of the molecule being extracellular. 
This extracellular domain, called extracellular domain 1 (ed1) is a binding site for C2. 
After binding, C2 is protected by CRIT from cleavage by activated C1s. Synthetic 
peptides of CRIT corresponding to ed1 and to an 11-amino acid peptide derived from the 
C-terminal end of ed1 were shown to have a strong inhibitory effect on the CP of 
complement activation [2, 3]. This inhibition is best explained by competition of ed1 of 
CRIT with C4b for C2 binding, and by the blockade of C2 cleavage by C1s.   
Very little is known about the topology and structure of the sites of C2, which 
lead to the assembly of the C4b-C2 and the CRIT-C2 complexes. Human C2 is a 102 kDa 
serum glycoprotein, 39% identical to its functional homologue factor B (FB) [4]. The 
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single polypeptide chain C2 is folded into three globular domains that were identified by 
electron microscopy [5]. The three complement control protein modules (CCP1, CCP2 
and CCP3) forming the N-terminal domain correspond to C2b. The larger C2a portion of 
the molecule is composed of a von Willebrand factor-A (vWFA) domain and a serine 
protease (SP) domain at the C-terminal end.  The initial binding of C2 to C4b occurs via 
two low affinity sites [6]. The first site located on the C2b domain is Mg2+ independent 
[7, 8], whereas the second site on the vWFA domain of C2a is Mg2+ dependent [9]. 
Nothing is known about the site(s) of C2 interaction with CRIT, although it might be 
speculated that the vWFA domain is responsible.     
 vWFA domains are a family comprising molecules of approximately 200 amino 
acids, most of which are components of the extra-cellular matrix and very often are the 
sites for protein-protein interaction in cell adhesion proteins, such as integrins [10, 11]. 
There is a highly conserved metal ion-dependent adhesion site (MIDAS) motif among 
46% of all vWFA domains, which is involved in ligand binding [11, 12]. In 1998, Schultz 
et al [13] compiled the SMART database (http://coot.embl-heidelberg.de/SMART), 
which lists all the known vWFA domains; 601 vWFA domains in 452 proteins. Through 
the intensive research of vWFA domains over the past six years, there has been a drastic 
increase in the number of vWFA domains and now 2863 vWFA domains in 2230 
proteins are listed in the SMART database. Fifty-three structures containing vWFA 
domains have been solved as the important widely expressed vWFA domain has been 
drawing an increasing degree of attention. 
 The recombinant expression system of the vWFA domain from human 
complement FB was successfully established in 1999 [14] and its crystal structure, which 
 68
reveals an integrin-like open conformation solved in 2004 [15]. However, unlike its 
functional homologue, FB, recombinant expression of C2 or its fragment has proved 
difficult and use of similar expression strategies (as for FB) has not worked well. 
Purification of C2 from human serum using antibody affinity chromatography [16] can 
only produce a reasonable amount of pure C2 for functional studies. Unfortunately, that 
quantity and quality of purified C2 from human serum will never be sufficient for 
structural studies, such as NMR and X-ray crystallography. 
 Study of the biological function of the vWFA domain in C2 requires the use of a 
suitable recombinant protein. In the present study, we report a successfully developed 
recombinant expression system for a functional vWFA domain in C2, which can aid in 
more precise studies of C2/C4 and C2/CRIT interactions [1, 2]. The most important issue 
will be the opportunity to perform the structural studies of C2 vWFA domain complexed 
with peptides corresponding to the binding site on C4 (a known specific sequence on C4β 
chain) or on CRIT (ed1 or H17) [2]. 
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EXPERIMENTAL 
Material 
The complement proteins C2 and C4 and the anti-C4 polyclonal antibody were purchased 
from Juro Supply AG (Switzerland).  Sheep erythrocytes and Amboceptor were from 
Bade Behring (Marburg, Germany). MagneHis protein purification system, Wizard plus 
minipreps kit and restriction enzymes were purchased from Promega (Switzerland). The 
human liver total RNA was from Ambion (Huntingdon, UK). Superscript III reverse 
transcriptase and AccuPrime Pfx DNA polymerase were obtained from Invitrogen 
(Switzerland). The EDTA-free protease inhibitor cocktail tablets came from Roche 
(Penzberg, Germany). The CRIT synthetic peptides:  
ed1 NH2- MSPSLVSDTQKHERGSHEVKIKHFSPY -CO2H 
H17 NH2-                                           HEVKIKHFSPY   -CO2H 
H17-2 NH2-                                           HEVKIKHFSPYHEVKIKHFSPY -CO2H 
were described elsewhere [2]. Underlined is the 11 amino acids sequence known to 
interact with C2. This sequence is double in H17-2. All other analytical grade reagents 
were purchased either from Sigma or Fluka Biochemika (Switzerland). 
 
Buffers 
TEDP buffer contained 20 mM Tris-HCl (pH7.6), 1 mM EDTA, 1 mM DTT and 0.001% 
PMSF. Ni2+-NTA chromatography buffer contained 20 mM Tris-HCl (pH 8), 400 mM 
NaCl and 2 mM β-mercaptoethanol. HiLoad 16/60 Sephadex 75 gel-filtration 
chromatography buffer made up with 20 mM Tris-HCl (pH 8), 100 mM NaCl, 5 mM 
MgCl2 and 2 mM DTT. GVB buffer (gelatin/veronal buffer) was prepared by mixing    
10 ml of 10 % (w/v) gelatin, 200 ml of 5X VB buffer (containing: 727 mM NaCl, 9 mM 
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Na barbitone and 3.1 mM diethylbarbituric acid; pH 7.4) and 790 ml water. GVB2+ buffer 
was prepared by mixing 200 ml GVB with 1 ml of 30 mM CaCl2 and 2 ml of 100 mM 
MgCl2. 
 
Electrophoresis and immunoblotting 
Electrophoresis was conducted using mini-gel systems (Bio-Rad, Hercules, CA) under 
reducing conditions. Proteins were separated by SDS-PAGE on 12 % gels. 
Immunoblotting to nitrocellulose membrane (Amersham Bioscience, UK) was performed 
as described previously [2]. 
 
Construction, expression and purification of vWFA-214 
Oligonucleotides were designed to flank the region of interest incorporating an NdeI 
restriction site and 6X His-tag at the 5’-end and EcoRI restriction site at the 3’-end for 
cloning and purification purposes. 1 μg total human liver RNA was used to synthesize the 
first-strand cDNA using Superscript III reverse transcriptase with oligo(dT)20 following 
the manufacturer’s recommended protocol. The synthesized cDNA was used to amplify 
the region of interest by PCR with the above synthetic oligonucleotides. The amplified 
PCR product (672 bp) was digested with NdeI and EcoRI and ligated into the pRUN 
vector (derived from pBR32), which was pre-digested with the same restriction enzymes. 
The ligation product was then transformed into XL1-Blue competent cells. The DNA 
sequence of the positive clone was verified by automated DNA sequencing, which was 
carried out on an ABI PRISM 3100 genetic analyzer using the ABI PRISM dye 
terminator ready reaction cycle sequencing kit (version 3, Applied Biosystems, 
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Switzerland) in both directions. Since this recombinant product contained 214 residues, it 
was denoted as vWFA-214. 
 vWFA-214 was expressed in the E. coli strain C41 (DE3) and pre-cultured at     
25 °C overnight. The overnight culture was diluted approximately 1:10 with fresh Luria 
broth medium containing 100 μg/ml ampicillin and the cells were grown at 18 °C until an 
absorbance A600 of 0.9 was attained. The cultures were then induced overnight with      
0.2 mM isopropyl β-D-thiogalactoside at 16 °C.  Cells were harvested in a Sorvall GS-3 
rotor at 6000 g for 10 min and frozen at -20 °C until required.   
 Cell pellets from 1.2 L culture were thawed and resuspended in 30 ml ice-cold 
TEPD buffer with addition of one protease inhibitor cocktail tablet. The cells were then 
lysed by three passages through a French Pressure Cell (SLM Instrument, Urbana IL, 
USA) and the lysate was centrifuged in a Sorval SS34 rotor at 40,000 g for 30 min. 
Streptomycin sulphate (10%, w/v) was added dropwise to the lysate to a final 
concentration of 1 % and stirred on ice for 20 min. The suspension was cleared by 
centrifugation at 40,000 g for 30 min. The supernatant was dialyzed against the Ni2+-
NTA chromatography buffer at 4 °C overnight. The next day, the dialyzed sample was 
centrifuged at 40,000 g for 30 min to remove debris. The supernatant was incubated with 
8 ml Ni2+-NTA resin (Qiagen, Switzerland) at room temperature for 1 h with gentle 
shaking, which was equilibrated with 40 ml Ni2+-NTA chromatography buffer, with 
addition of 30 mM imidazole. After incubation, the Ni2+-NTA resin was washed 
thoroughly with Ni2+-NTA chromatography buffer supplemented with 30, 60, and 90 mM 
imidazole respectively, until the absorbance A280 became zero. Then, the recombinant 
vWFA-214 was eluted with Ni2+-NTA chromatography buffer supplemented with 150 
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mM imidazole and collected in 1.5 ml fractions. The pooled fraction was dialyzed against 
the HiLoad 16/60 Sephadex 75 gel filtration chromatography buffer at 4 °C overnight. 
After dialysis, the partially purified recombinant vWFA-214 was centrifuged at 40,000 g 
for 30 min and concentrated using a Millipore Centricon 10 unit at 4 °C, to 1 ml. The 
concentrated sample was loaded onto a calibrated FPLC HiLoad 16/60 Sephadex 75 gel-
filtration column (Amersham Bioscience, UK). The partially purified vWFA-214 was 
further purified by gel filtration at a flow rate of 1 ml/min and collected in 2 ml fractions. 
As assessed by SDS-PAGE, the fractions containing pure vWFA-214 were pooled and 
stored at -20 °C. 
 
Antibodies 
Polyclonal rabbit anti-CRIT-ed1 antibody was derived as described before [2]. 200 μg of 
KLH-CRIT-ed1 in PBS, emulsified with CFA was administrated on day 21 and with IFA 
on day 28, and was followed by subsequent injections with 100 μg of KLH-CRIT-ed1 on 
days 35, 50 and 60. At day 60, rabbit polyclonal anti-CRIT-ed1 serum was affinity-
purified using an ed1 epoxy-activated Sepharose 6B (Sigma-Aldrich, Switzerland) 
column. 
Polyclonal anti-vWFA antibody was produced in mouse ascitic fluid according to 
a method described elsewhere [17, 18]. In brief, 10 μg of purified vWFA-214 was 
electrophoresed on SDS-PAGE and the gel was stained with 0.01 % Coomassie blue for 
30 min. After staining, the gel was washed four times in distilled water for 15 min each. 
The band containing vWFA-214 was excised and emulsified in 200 μl 1X PBS by 
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passing ten times through a 1 ml syringe and finally several times through a 21 G needle. 
The emulsified gel was injected intraperitoneally into Balb/c mice. 
 
MagneHis Ni-Particles pull-down assay 
MagneHis Ni-Particles pull-down assays were performed according to the manufacturer’s 
protocol (Promega, Switzerland) with some modifications. Briefly, 3 μg of purified 
recombinant vWFA-214 was diluted in 50 μl binding/wash buffer included in the kit and 
mixed with 20 μl MagneHis Ni-Particles at room temperature for 30 min with gentle 
shaking. After incubation, the tube was placed in a magnetic stand for 1 min to allow the 
MagneHis Ni-Particles to be captured by the magnet and the supernatant was removed. 
The MagneHis Ni-Particles were washed three times with the binding/wash buffer. 5 μg 
of pure C4 protein (diluted in 50 μl binding/wash buffer) or 50 μl of freshly prepared 
normal human serum (NHS; 1:50 dilution) was added and incubated for 20 min. After 
washing three times, the vWFA-214-C4 complex was eluted, subjected to SDS-PAGE, 
and detected by Western blotting with polyclonal antibody against C4. 
 
Hemolytic assay 
The inhibition of CP based haemolysis was conducted as described elsewhere [19, 20]. In 
brief, sheep erythrocytes were washed three times with ice-cold GVB/10 mM EDTA. The 
antibody sensitized sheep erythrocytes (EA, 2 x 108 cell/ml) were prepared by mixing 
equal volume of washed sheep erythrocytes and Amboceptor (1:40 dilution), which was 
incubated for 30 min at 37 °C. Different amounts of purified vWFA-214 (5, 10, and      
20 μg) were mixed with different volumes of diluted NHS (1:100 dilution; 0, 20, 40, 60, 
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80, 100 and 120 μl) and made up to 150 μl with freshly prepared GVB2+ buffer, which 
was then pre-incubated for 30 min at room temperature. After the pre-incubation, 50 μl 
EA was added and incubated for 30 min at 37 °C. Background control was obtained by 
incubating NHS with GVB2+ buffer and 100 % lysis was determined by adding distilled 
water to EA. The degree of complement haemolysis was determined by measuring the 
absorbance of the supernatant at 414 nm on a SpectraMAX 190 microtitre plate reader 
(Molecular Devices, Sunnyvale, CA). 
 
Purification of C4 chains 
Pure C4 protein was separated by SDS-PAGE on a 12 % gel under reducing conditions. 
After electrophoresis and destaining, the bands containing C4α, β and γ chains were 
excised separately. The C4 chains were eluted from the gel with the Millipore Micro-
Electro-eluter according to the manufacturer’s protocol. Electro-elution was carried out 
using the Millipore Centricon YM-10 at 150 V for two hours. The concentration of the 
eluted C4 chains was estimated by the Bradford reagent (Bio-Rad, Hercules, CA). 
 
Sandwich ELISA 
The microtiter plate was coated with 100 μl diluted anti-vWFA antibody (1:1000 in      
0.1 M Bicarbonate buffer, pH 9) overnight at 4 °C. The plate was emptied and washed 
five times with wash buffer (0.05 % Tween-20 in PBS). The unoccupied sites were 
blocked with blocking buffer (PBS with 0.2 % Tween-20 and 2 % BSA) for 1 h. vWFA-
214 was diluted in blocking buffer and 100 μl was added to each well (1 μg per well) and 
incubated at RT for 1 h. Next, 100 μl diluted C4 or purified C4 chains (0.5, 2.5, 5 or      
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25 nM) was added and incubated for 1.5 h. A 1:5000 dilution of anti-C4 antibody was 
prepared and 100 μl was added and incubated for 1 h. Then, the anti-goat HRP secondary 
antibody (1:3000) was added to each well and incubated for 45 min. After this step, the 
plate was washed thoroughly and 100 μl tetramethylbenzidine substrate (TMB substrate 
reagent set, BD Bioscience, San Diego, CA) was added to each well and incubated for 
approximately 5-10 min, until the wells turned blue. 50 μl of 2 N H2SO4 was added to 
each well to stop the reaction. The binding activity was determined by measuring the 
absorbance at 450 nm. All the incubations were carried out at room temperature and after 
each incubation step, the plate was washed at least five times with washing buffer. The 
samples and antibodies were diluted with blocking buffer. A background control was 
included either without vWFA-214 or native C4/C4 chains. 
 
vWFA-214-CRIT ligand blotting 
vWFA-214 (2 μg) was mixed with CRIT peptides (1.5 μg) in PBS and incubated on ice 
for 2 h. Disuccinimidyl suberate (DSS) cross-linker (Perbio Science, Switzerland) was 
dissolved in DMSO and added to the reaction mixtures to a final concentration of 2 mM. 
The reaction mixtures were incubated for a further 2 h on ice. At the end of the 
incubation, 1 M Tris-HCl, pH 7 was added to a final concentration of 40 mM to quench 
the reaction. The vWFA-214-CRIT complexes were analyzed by probing with anti-CRIT 
antibody in Western blots. For the blocking experiment, vWFA-214 (2 μg) was pre-
incubated with anti-vWFA antibody (1:500 dilution) on ice for 2 h and the ligand blot 
was carried out as described above.  
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RESULTS AND DISCUSSION 
Expression and purification of the vWFA-214 domain of C2 
Recombinant expression of C2 or its fragment proved to be difficult. Unlike its functional 
homologue FB, in which Cys267 is absent, the yield and solubility of C2 vWFA domain 
cannot be improved by introducing a Cys267 → Ser mutation [14]. Even though there is 
another free Cys (residue 241) in the C2 vWFA domain, Cys241 was shown to be essential 
for the normal assembly and decay of C3 convertase [9, 21, 22]. The expression of 
vWFA-214 at 37 or 30 °C, resulted in the serious problem of inclusion body formation. 
To overcome this problem, we expressed vWFA-214 at 16 °C and the result was a good 
level of expression (6-8 mg per liter of bacterial culture). The solubility of vWFA-214 
was very good, with no aggregation or precipitation occurring during short-term storage 
at 4 °C or long-term storage at -20 °C (1 mg/ml or 15 mg/ml). 
The recombinant vWFA-214 (214 amino acids) domain was expressed as a His-
tag fusion protein. The predicted molecular mass was 25 kDa. By matrix-assisted laser 
adsorption ionization (MALDI) MS, vWFA-214 showed a prominent single peak in clean 
spectra with mass of 25244, which was in good agreement with the predicted mass of 
25252. Figure 1A shows the SDS-PAGE analysis of vWFA-214 after both Ni2+-NTA and 
gel filtration chromatography. The yield was estimated using both the Bradford reagent 
and the absorbance at 280 nm at 6-8 mg per liter of bacterial culture. The purified vWFA-
214 protein was used to raise the polyclonal antibody in mouse for the functional studies. 
Figure 1B shows the specificity of this anti-vWFA antibody against C2 and the 
recombinant vWFA-214. 
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Figure 1   Expression and purification of the recombinant vWFA-214 domain 
 
(A) SDS-PAGE analysis of different stages in the expression and purification of the 
recombinant vWFA-214 domain. Lane 1, total E. coli cell lysate after overnight induction 
at 16 °C with 0.2 mM isopropyl β-D-thiogalactoside. The major band at approximately 
25 kDa represents the His-tag vWFA-214 fusion protein. Lane 2, loss of the 25 kDa His-
tag vWFA-214 fusion protein after incubation with Ni2+-NTA resin. Lane 3, His-tag 
vWFA-214 fusion protein eluted with 150 mM imidazole.  Lane 4, purified vWFA-214 
fusion protein after additional HiLoad 16/60 Superdex 75 gel filtration chromatography. 
(B) Western blot showing that the antibody raised against vWFA-214 (1:1000 dilution) 
detects intact C2 and the recombinant vWFA-214 in an E. coli cell lysate. Lane 1, 1 μg 
intact C2. Lane 2, total E. coli cell lysate (lane 1 in Figure 1A). Lane 3, 500 ng purified 
vWFA-214 fusion protein (lane 4 in Figure 1A). 
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Functional binding of vWFA-214 to C4 
The recombinant vWFA-214 domain provided a unique opportunity to study its 
functional activity as work on the isolated vWFA domain had not previously been 
possible. The interaction between vWFA-214 domain and C4 was first investigated by a 
pull down assay using MagneHis Ni-particles. The vWFA-214 immobilized onto the 
MagneHis Ni-particles interacted with C4 and was successfully pulled down either pure 
C4 (Figure 2A) or C4 in NHS (Figure 2B). In order to show that C4 was present in the 
elution from vWFA-214-NHS pull-down assay, Western blotting was performed. After 
probing with anti-C4 antibody it was clearly shown that C4 in NHS interacted with and 
was pulled down by the immobilized vWFA-214. The negative control, pull-down assay 
with MagneHis Ni-particles and NHS without vWFA-214, showed that C4 in NHS did 
not interact with MagneHis Ni-particles (Figure 2B, lane 3). The low intensity of the 
band corresponding to the C4α chain (Figure 2B, lane 2) is probably due to degradation 
by Factor I during incubation times. In the presence of Factor H or C4-binding protein in 
NHS, Factor I degrades the C4α chain into C4d and α4 [23]. 
  In using C2 deficient serum (obtained from a patient with type I complement C2 
deficiency) in the hemolytic assay, vWFA-214 could not restore the hemolytic activity 
because of the absence of the serine protease domain [6, 24]. Figure 3 shows the 
inhibitory effect of vWFA-214 on the CP of complement activation. In the hemolytic 
assay using NHS, the recombinant vWFA-214 domain was able to inhibit the hemolysis 
by  competing  with  intact  C2 in  NHS for  C4b  binding  in  a  dose  dependent  manner.          
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Figure 2   Interaction of C4 with the recombinant vWFA-214 by MagneHis Ni-
Particles pull-down assay. 
 
(A) 3 μg purified His-tag vWFA protein was bound to the MagneHis Ni-Particles. Pure 
C4 protein interacted with vWFA protein and was retained on the MagneHis Ni-Particles. 
The pull-down assay results were analyzed by SDS-PAGE, under reducing conditions, 
stained with Coomassie Blue. Lane 1, 500 ng vWFA protein. Lane 2, unbound C4 in the 
flow through. Lanes 3-5, three times 50 mM imidazole washing. Lane 6, elution of C4 
from vWFA-214-C4 pull-down assay. (B) C4 of NHS was retained on MagneticHis Ni-
particles. Western blotting probed with anti-C4 antibody confirming that C4 present in 
the elution from vWFA-214-NHS pull-down assay using NHS. Lane 1, 500 ng C4 
protein. Lane 2, 20 μl of elution from vWFA-214-NHS pull down assy. Lane 3, 20 μl of 
elution from negative control, pull-down assay using NHS without vWFA-214. 
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In the presence of 2.5 μg vWFA-214, there was minimal inhibition of hemolysis (data not 
shown). 8.26 % of inhibition was observed with 5 μg vWFA-214 and this increased to 
20.54 % and to a maximum 44.93 % with 10 and 20 μg vWFA-214 respectively.  
 By site-directed mutagenesis, Horiuchi et al [9] showed that Cys241 in the C2 
vWFA domain is important for C4b binding and predicted the presence of a C4b binding 
site within the vWFA domain region around Cys241. Although site-directed mutagenesis 
is a powerful tool to study protein-protein interaction, substitution of important amino 
acid(s) may result in conformational change of the binding site, which eventually loses its 
binding activity. In the current study, we clearly demonstrate the presence of a C4 
binding site in the isolated C2 vWFA-214 domain. Further experiments may be needed to 
delineate the exact binding site of C4 in the vWFA-214 domain. 
 
vWFA-214/C4 interaction through C4β chain 
Having confirmed the presence of a C4 binding site on the functional recombinant 
vWFA-214 domain, we were curious to define which chain(s) of C4 mediate(s) the 
vWFA-214/C4 interaction. To study this, C4 was separated into C4α, β and γ chains by 
SDS-PAGE and each C4 chain was purified by electro-elution. Figure 4A shows the 
SDS-PAGE of the purified C4 chains. Western blotting, probed with anti-C4 antibody, 
was also performed to confirm that the anti-C4 antibody recognized all three purified C4 
chains (Figure 4B). Sandwich ELISA was then performed to investigate the interaction 
between vWFA-214 and the purified C4 chains using pure C4 as a positive control. 
Figure 4C shows the binding curves generated from the sandwich ELISA data. For C4α 
and  C4γ  chains,  there   is   only   negligible   interaction  with  the  vWFA-214  domain.  
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Figure 3  Inhibition of classical complement pathway activation by  the recombinant 
vWFA-214 protein. 
 
Different amounts of recombinant vWFA-214 proteins were pre-incubated with NHS for 
30 min at room temperature before adding to the sensitized sheep erythrocytes. The 
recombinant vWFA-214 protein competed with C2 in NHS for C4 binding and decreased 
the % hemolysis in a dose dependent manner. The results show the mean ± standard 
deviation (SD) of three independent experiments each of duplicate measurements. 
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Figure 4   Sandwich ELISA of C4 and purified C4 chains with the recombinant 
vWFA-214 protein. 
 
(A) C4 protein was separated into C4α, C4β and C4γ chains by 12 % SDS-PAGE, under 
reducing conditions. After electrophoresis, the gel was stained with Coomassie Blue and 
the separated C4 chains were excised and purified by electro-elution. Lane 1, 500 ng pure 
C4 protein. Lane 2-4, each loaded with 500 ng purified C4α, C4β and C4γ chain 
respectively. (B) Western blotting confirming that anti-C4 antibody recognizes each of 
the purified C4 chains. Lane 1, 500 ng pure C4 protein. Lane 2-4, each loaded with 500 
ng purified C4α, C4β and C4γ chain respectively. (C) Sandwich ELISA to investigate the 
binding of vWFA-214 to C4/C4 chains shows the presence of a C4 binding site on the 
vWFA-214. The binding affinity of intact C2 and recombinant vWFA-214 protein to 
C4/C4 chains was nearly the same (data not shown). It was also revealed that the 
interaction between C4 and C2 was mediated through the C4β chain and vWFA-214 
domain. The results show the mean ± SD of three independent experiments each of 
duplicate measurements. 
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By contrast, C4β chain has significant binding with vWFA-214 domain, which saturated 
similarly to the native C4. On the basis of this, we conclude that the vWFA-214 domain 
most probably interacts with C4 via its β chain.  
Since there are other demonstrated or suggested C4b binding sites on C2 
(respectively on C2b) [7-9]  and SP domains of C2a [25, 26], we compared the binding of 
intact C2 and recombinant vWFA-214 protein for C4/C4 chains. The binding curves for 
C2 were however almost identical to those observed for recombinant vWFA-214 with 
binding to intact C4 and the C4β chain only. Although these experiments do not allow an 
evaluation of the possible contribution of additional binding sites, the interaction between 
vWFA and the C4β chain appears to be central to explain the binding of C2 to C4b at 
equilibrium. The structural study of vWFA-214 domain should help to better define this 
binding. 
 
Functional binding of vWFA-214 to CRIT peptides 
Previously we have described that CRIT binds to the C2a portion of C2 and inhibits the 
formation of the CP C3 convertase [2]. We tested whether the recombinant vWFA-214 
domain bound to CRIT using cross-linking agent (DSS). CRIT peptides of different sizes 
but including the C2 binding site on ed1 (ed1, H17 or H17-2) were first incubated with 
vWFA-214. Then the complexes formed were cross-linked with DSS, immunoblotted and 
probed with anti-CRIT antibody. Since this antibody was raised against whole ed1, it 
reacted against all three peptides. As shown in Figure 5A, the CRIT peptides (ed1, H17 
and H17-2) bound to vWFA-214 and the signals were specific. In a separate set of 
experiments, the  binding of  CRIT/vWFA-214  could be  blocked by pre-incubation with  
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Figure 5   Ligand blot of the recombinant vWFA-214 and CRIT peptides showing 
the presence of a CRIT binding site on vWFA-214. 
 
(A) The recombinant vWFA-214 protein was incubated with CRIT peptides and the 
resulting complexes were cross-linked with or without DSS. Those complexes not cross-
linked with DSS were used as a control. After cross-linking, the complexes were detected 
by immunoblotting and probing with polyclonal anti-CRIT antibody which recognizes 
ed1, H17 and H17-2. The results showed that the recombinant vWFA-214 protein 
interacted with CRIT ed1 and H17 peptides. It also interacted weakly with H17-2 
peptide. The negative control included CRIT peptides and vWFA-214 protein without 
DSS corsslinker. (B) The interaction between vWFA-214 and CRIT H17 could be 
blocked by the pre-incubation of recombinant vWFA-214 protein with anti-vWFA 
antibody (1:500 dilution).  
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polyclonal anti-vWFA antibody (Figure 5B). These results indicated that the vWFA 
domain of C2 binds the peptide sequence of CRIT known to interact with C2. 
 The amino acid sequence of CRIT-ed1 and CRIT-H17 show 35 % and 55 % 
identity with a specific sequence in the C4β chain (S206-Y232) respectively [2]. In 
addition, Horiuchi et al [9] showed by site-directed mutagenesis that there is evidence for 
a C4b binding site around residue Cys241 of the C2 vWFA domain. In view of this, there 
is a high possibility that both CRIT and the C4β chain act on the same or similar region 
within vWFA-214 domain, possibly the perfectly conserved MIDAS motif. The structural 
study by X-ray crystallography with co-crystallization of vWFA-214/CRIT and vWFA-
214/C4β chain peptide complexes should give an insight into their common region of 
interaction. In addition, the ligand-binding function of C2 vWFA domain can now be 
included in the SMART database of the vWFA domain superfamily.  
 In conclusion, the vWFA-214 domain of C2 appears to play a central role 
in the interactions of C2 with C4 and CRIT. The use of this recombinant domain may 
help to further clarify the fine molecular interactions between these proteins, a better 
understanding of which may help to develop a synthetic inhibitor capable of blocking 
activation of complement by the classical pathway. Such a reagent might be of great 
clinical utility in diseases mediated by the formation of immune complexes.  
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ABSTRACT 
Complement C2 receptor inhibitor trispanning (CRIT) inhibits the classical pathway (CP) 
C3 convertase formation by competing with C4b for the binding of C2. The C terminal 
11 amino acid of the first CRIT-extracellular domain (CRIT-H17) have a strong 
homology with a sequence in the C4β chain, which is responsible for the binding of C2. 
Since the CP and alternative pathway (AP) C3 convertases have many functional and 
structural similarities, we further investigated the effects of CRIT-H17 on the AP. The 
cleavage of factor B (FB) in the presence of C3b and factor D (FD) was blocked by 
CRIT-H17 but not by control peptides. By immunoblots using a cross-linking agent, 
CRIT-H17 was shown to bind FB and its two fragments, Ba and Bb, and C3b but not FD. 
The binding to FB was three fold higher than to C3b by ELISA. These data suggested 
that CRIT-H17 lies across the junction of the FD cleavage site. CRIT-H17 had no decay 
activity on the C3bBb complex as compared to decay-accelerating factor. In a hemolytic 
assay using C2 deficient serum, CRIT-H17 inhibited partially complement activation by 
the AP. Additional experiments showed that CRIT-H17 inhibited slightly the factor I-
mediated cleavages of C3b in the presence of factor H or CR1 indicating that the 
regulatory role of CRIT-H17 is complex, probably related to its dual binding to FB and 
C3b. These findings reemphasize the analogies between both the AP and CP C3 
convertases formation, and should help us to define the exact molecular contacts.  
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INTRODUCTION 
The complement system consists of about 30 proteins, and is an important component of 
both innate and acquired immunity [1, 2], which mediates acute inflammatory and 
cytolytic reactions. It plays an important role in host defense and in the elimination of 
invading foreign pathogens. There are three separate pathways to activate the 
complement system; classical, alternative, and lectin pathways and several regulatory 
proteins to control the complement activation. Each pathway responds to different 
activators and activates the complement system in a sequential manner but all three 
pathways converge in the assembly of the C3 convertase and end in the formation of 
C5b-9, known as the membrane attack complex.   
 The classical pathway (CP)3 relies on antibody to initiate activation of the C1 
molecule and the mannan-binding lectin pathway is initiated by binding of mannan-
binding lectin to sugar residues on pathogen surfaces. Besides the initiating factors, these 
two pathways are identical. The activation of the alternative pathway (AP) is Ab-
independent and generates a distinct C3 convertase, C3bBb. The AP provides an 
immediate line of defense to foreign particles due to the spontaneous hydrolysis of the 
internal thioester bond in plasma C3 to form C3(H2O), which has an altered conformation 
allowing the binding of factor B (FB) [3, 4]. The first step in AP is the nucleophilic attack 
on the internal thioester bond in C3b by an amine or hydroxyl group on the pathogen 
surfaces, followed by binding of FB which forms the C3bB complex [5]. The Ba 
fragment of FB is involved in the initial interaction with C3b [6, 7] and both the von 
Willebrand factor-A (vWFA) domain and the serine protease (SP) domain of the Bb 
fragment interact with C3b [8, 9]. Binding to C3b induces a conformational change in FB 
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which in turn becomes susceptible to the cleavage by factor D (FD). The FD-mediated 
cleavage of FB is the rate-limiting step for generating the AP C3 convertase, C3bBb. 
However, the exact mechanism of assembling this bimolecular complex, C3bBb, is still 
under investigation even 50 years of the discovery of the AP [10]. 
 As a protective mechanism, there are several complement regulatory proteins that 
protect self from the potentially destructive effects of complement activation. These 
proteins belong to the regulators of complement activation (RCA) gene family, which are 
encoded in the gene cluster on the long arm of chromosome one[11]. The RCA proteins 
control complement activation by either promoting an irreversible dissociation of 
complement convertases or acting as cofactors in the factor I (FI) mediated cleavage of 
C3b. The RCA proteins, decay accelerating factor (DAF), factor H (FH) and complement 
receptor 1 (CR1) are responsible for the dissociation of complement convertases and 
membrane cofactor protein (MCP), FH and CR1 act as cofactors in the FI-mediated 
cleavage of C3b. There is one common structural motif among the RCA gene family 
termed the short consensus repeat (SCR), which comprises approximately 60 amino acids 
and shares 20-40 % homology with each other.       
 Previously, we described a novel human complement CP inhibitor, complement 
C2 receptor inhibitor trispanning (CRIT), which is expressed on hemopoietic cells and in 
a wide range of tissues [12]. The first extracellular domain (ed1) is a binding site of C2. 
After binding, C2 is protected by CRIT from the cleavage by activated C1s. Synthetic 
peptides corresponding to CRIT-ed1 and to the C-terminal 11 amino acid of CRIT-ed1 
(CRIT-H17) were shown to have a strong inhibitory effect on the CP of complement 
activation [13, 14]. This inhibition is best explained by competition of CRIT-ed1/CRIT-
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H17 with C4 for C2 binding, and by the blockade of C2 cleavage by C1s. Later, we 
expressed the recombinant C2 vWFA domain and further demonstrated that there is a 
CRIT binding site on the C2 vWFA domain [15].  
 Since there are many common features between the complement CP and AP and 
many proteins in the CP function in a manner analogous to those of the AP, we further 
studied the regulatory effects of CRIT-H17 in the AP. In the AP, C3b, FB and FD serve 
as functional analogues to that of C4b, C2 and C1s of the CP, respectively. We started the 
studies with a hypothesis that CRIT-H17 interacts with FB and possibly inhibits the FD-
mediated cleavage of FB. This report describes the novel regulatory properties of CRIT-
H17 in the AP.   
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EXPERIEMENTAL 
Reagents 
The complement proteins FI and FH and the anti-Ba and anti-Bb monoclonal antibodies 
were purchased from Quidel (San Diego, CA). FB and C3b protein were obtained from 
Juro Supply AG (Lucerne, Switzerland). Recombinant soluble human CR1 was kindly 
provided by T-cell Science (Cambridge, MA). Recombinant DAF was a gift from Dr. 
I.W. Caras (Genentech, San Francisco). FD was purified from the peritoneal fluid of 
patients with end stage renal failure on chronic ambulatory peritoneal dialysis [16]. 
Polyclonal rabbit anti-CRIT antibody was derived as described previously [13, 15]. 
Rabbit erythrocytes (Erab) were from Bade Behring (Marburg, Germany). The C2-
deficient serum (C2-D) was obtained from a patient with type I complement C2 
deficiency. Disuccinimidyl suberate (DSS) cross-linking reagent was obtained from 
Perbio Science (Lausanne, Switzerland). ProteoBlue staining solution was purchased 
from Qbiogene (Basel, Switzerland). The CRIT synthetic peptides: ed1 
(MSPSLVSDTQKHERGSHEVKIKHFSPY), H17 (HEVKIKHFSPY), H17S (scramble 
peptide of H17) (EKFYHIHSKPY) and H17-2 (HEVKIKHFSPYHEVKIKSPY) and 
human C4β  chain peptides: Hu-C4β chain F212 (FEVKKYVLPN) and Hu-C4β chain F222 
(FEVKITPGKPY) were described elsewhere [13]. All other analytical grade reagents 
were purchased from Sigma or Fluka Biochemika (Buchs, Switzerland). 
 
Buffers 
GVB (gelatin/veronal buffer) was prepared by mixing 10 ml of 10 % (w/v) gelatin,      
200 ml of 5x VB (veronal buffer, containing 727 ml NaCl, 9 mM sodium barbitone and 
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3.1 mM diethylbarbituric acid, pH 7.4) and 790 ml of water. GVB-Mg2+-EGTA buffer 
was prepared by mixing 50 ml 100 mM EGTA, 35 ml 200 mM MgCl2, 104 ml GVB,   
311 ml 5 % (w/v) D-glucose and adjusted to pH 7.4.  
 
Electrophoresis and immunoblotting 
Electrophoresis was conducted using a mini-gel system from Bio-Rad (Hercules, CA). 
Proteins were separated by SDS-PAGE on 10 % gels under reducing or non-reducing 
condition. Immunoblotting on to nitrocellulose membrane (Amersham Biosciences, 
Bucks, UK) was performed as described previously [13]. 
 
FB cleavage 
FB was cleaved by incubating 500 ng FB, 200ng FD and 200 ng C3b at 37 °C for 60 min. 
The reaction was stopped by adding SDS-PAGE loading buffer. In some experiments, 
different amount (10-100 μg) of either CRIT or C4β chain peptides were pre-incubated 
with FB for 30 min at RT before adding other components. After the incubation, the 
reaction mixtures were analyzed by SDS-PAGE under non-reducing condition and the 
gel was stained with ProteoBlue staining solution. 
 
AP components-CRIT ligand blotting 
AP components FB (500 ng), FD (500 ng), C3b (500 ng), mixture of FB and C3b (500 ng 
each) and FB cleavage reaction mixture were mixed with CRIT-H17 (1.5 μg) in PBS and 
incubated at RT for 30 min. DSS cross-linker was dissolved in DMSO and added to the 
reaction mixtures to a final concentration of 2 mM. The reaction mixtures were then 
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further incubated at RT for 30 min. At the end of the incubation, 1 M Tris-HCl,  pH 7, 
was added to a final concentration of 40 mM to quench the reaction. The AP 
components-CRIT-H17 complexes were analyzed by SDS-PAGE under reducing 
condition and probing with anti-CRIT Ab in Western blot. 
 
Hemolytic assay 
The inhibition of AP-based hemolysis was conducted using the standard method 
described in the literature [17, 18]. In brief, Erab (2 x 108 cells/ml) were prepared in 
GVB-Mg2+-EGTA buffer. 10 μM of CRIT peptides (ed1, H17 and H17-2) were mixed 
with different volumes of diluted C2-D (1:20 dilution; 0, 20, 40, 60, 80, 100 and 120 μl) 
and made up to 150 μl with freshly prepared GVB-Mg2+-EGTA buffer, which was then 
pre-incubated at RT for 30 min. After the pre-incubation, 50 μl of Erab was added and 
incubated at 37 °C for 30 min. Background control was obtained by incubating C2-D 
with GVB-Mg2+-EGTA buffer, and 100 % lysis was determined by adding distilled water 
to Erab. After 5 min centrifugation at 1000 g, the degree of complement hemolysis was 
determined by measuring the absorbance of the supernatant at 414 nm on a SpectraMax 
190 microtitre plate reader (Molecular Devices, Sunnyvale, CA).   
 
ELISA of CRIT-H17 with FB and C3b 
The microtitre plate was coated with either 55 nM FB or C3b, prepared in 0.1 M 
bicarbonate buffer pH 9, at 4 °C overnight. The plate was emptied and washed five times 
with washing buffer (0.05 % Tween 20 in PBS). The unoccupied sites were blocked with 
blocking buffer (PBS with 0.2 % Tween 20 and 2 % BSA) for 1 h. 100 μl of CRIT-H17 
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(5, 10, 20 and 40 μM) was added and incubated for 1 h. A 1:100 dilution of anti-CRIT 
antibody was prepared and 100 μl was added and incubated for 1 h. Then, the anti-rabbit 
HRP secondary antibody (1:3000) was added to each well and incubated for 45 min. The 
plate was washed thoroughly, and 100 μl of tetramethylbenzidine (TMB) substrate 
reagent set (BD Biosciences, San Diego, CA) was added to each well and incubated for 
approximately 5-10 min, until the wells turned blue. A 50 μl volume of 1 M H2SO4 was 
added to each well to stop the reaction. The binding activity was determined by 
measuring the absorbance at 450 nm. All the incubations were carried out at RT, and 
after each incubation step, the plate was washed at least five times with washing buffer. 
The samples and antibodies were prepared in blocking buffer. The plate coated with 2 μg 
BSA and incubated with 40 μM CRIT-H17 was used as control. 
 
Generation and decay of C3bBb-Ni2+ complexes 
For the generation of C3bBb-Ni2+ complexes, C3b-coated (500 ng) microtitre wells were 
incubated with 50 ng FB and 3 ng FD in reaction buffer (phosphate buffer supplemented 
with 5 mM NiCl2, 25 mM NaCl, 4 % BSA and 0.05 % Tween 20) at 37 °C for 2 h [6, 19]. 
After the formation of C3bBb-Ni2+ complexes, the plate was washed five times with 
reaction buffer and further incubated either with reaction buffer or CRIT-H17 (50 μg) or 
DAF (5 and 10 ng) at RT for 30 or 60 min. After the incubation, C3bBb-Ni2+ complexes 
were detected by ELISA employing anti-Bb monoclonal antibody (1:5000 dilution).  
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FI-mediated cleavage of C3b 
The cleavage reaction was performed by incubating C3b (500 ng) with FH (500 ng) or 
CR1 (500 ng) and FI (100 ng) at 37 °C for 2 h. In some experiments, C3b was pre-
incubated with CRIT peptides (10, 50 and 100 μg) at RT for 30 min before addition of FI 
and cofactor FH or CR1. The cleavage products were analyzed by SDS-PAGE under 
reducing condition and the gel was stained with ProteoBlue staining solution. 
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RESULTS 
Sequence alignments between CRIT-H17 and the Hu-C4β chain peptides 
In previous studies, the CRIT-H17 has been demonstrated to be an effective inhibitor of 
the CP [13]. The blockade of the CP was more efficient with CRIT-17 than with CRIT-
ed1, suggesting that it corresponds to the active sequence. Two sequences showing 
homologies with CRIT-17 in the β chain of C4 have been previously identified. 10 and 
11 aa peptides corresponding to these sequences are both as potent inhibitors of the CP as 
CRIT-H17: C4β F212 and C4β F222 share 45 % identity and have 45 % and 55 % identity 
with CRIT-H17 respectively (Figure 1). In 2001, Laich et al. [20] demonstrated with 
surface plasmon resonance that compared to the affinity between C2 and C4b, FB 
interacts only weakly with immobilized C4b. Thus, these two C4β chain peptides were 
included in the studies on the regulation of the AP. CRIT-H17S is a peptide with amino 
acid identical to CRIT-H17 but in a scrambled sequence, (Figure 1), which does not 
inhibit the CP. CRIT-H17S peptide was used as a control. 
  
Inhibition of FD-mediated cleavage by CRIT-H17 and weakly by C4β F212 
FB binds to C3b and is immediately cleaved by FD into Ba and Bb fragments, with Bb 
remaining attached to C3b forming the AP C3 convertase, whereas Ba is released. When 
CRIT-H17 was pre-incubated with FB before the addition of FD and C3b, FB cleavage 
was inhibited and less Ba and Bb fragments were formed. This inhibiton was dose 
dependent as shown in Figure 2A, with a complete inhibition at the highest concentration 
of CRIT-H17 used. The control peptide CRIT-H17S, which shares only 18 % identity 
and   55 %  similarity   with  CRIT-H17,  had  no  inhibitory  effect  on  the  FD-mediated  
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Figure 1   Amino acid sequence alignments of CRIT-H17 and human C4β chain 
peptides showing similarities between different peptides.  
 
Alignments were made using the MAFFT program. Periods indicate similar residues and 
asterisks indicate identical residues. The dash line box shows the potential region 
responsible for blocking FD-mediated cleavage of FB. 
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cleavage of FB. 
Since CRIT-H17 and the two C4β chain peptides showed high sequence 
homology and comparable inhibitory effect in the CP activation, we were intrigued to see 
whether these peptides would interfere with the cleavage of FB as well. As shown in 
Figure 2B, the C4β chain F212 peptide showed inhibition of FB cleavage, although only a 
partial inhibition at the highest concentration tested, whereas the C4β chain F222 peptide 
did not have any measurable inhibitory effect. However, these data indicated that 
peptides derived from CRIT and one of its homologous region in the C4β chain were 
capable to interfere with the formation of both, the CP and AP C3 convertases. 
  Referring to Figure 1, we were surprised that the C4β chain F222 peptide, with no 
inhibitory activity, had even higher sequence homology with CRIT-H17 than the C4β 
chain F212 peptide. The dash line box highlights the region showing the major differences 
between these two C4β chain peptides and CRIT-H17. In addition, it highlights the 
potential region responsible for blocking the FD-mediated cleavage of FB. At close 
scrutiny, it appears that the additional proline residue in the C4β chain F222 peptide may 
induce a change from cis- to trans-conformation or vice versa [21, 22]. Also, this proline 
residue may possess certain degrees of steric hindrance in the interaction between FB and 
the C4β chain F222 peptide. Thus, this C4β chain F222 peptide loses its inhibitory effect on 
the FD-mediated cleavage of FB. 
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Figure 2  CRIT-H17 and C4β F212 peptides but not CRIT-H17S and C4β F222 
peptides inhibit the FD-mediated cleavage of FB.  
 
FB (500 ng) was pre-incubated with either CRIT or C4β peptide for 30 min at RT before 
adding FD (200 ng) and C3b (200 ng). The mixtures were then further incubated for 60 
min at 37 °C. The effect of increasing concentrations (10 – 100 μg) of CRIT (A) and C4β 
(B) peptides on the cleavage of FB by FD were analyzed by SDS-PAGE (10% gel) under 
non-reducing conditions, stained with ProteoBlue staining solution. 
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CRIT-H17 peptide interacts with FB and C3b but not FD 
From the analogy to the CP, we predicted that CRIT-H17 would bind to FB, with at least 
one binding site of the vW domain of Bb, since CRIT-H17 binds C2 and has at least one 
binding site on the vW domain of C2. First the binding was tested using a cross-linking 
agent, DSS and immunoblots to reveal the bound CRIT-H17 to its target protein. As 
shown in Figure 3, in various mixtures of C3b, Factor B and FD, there was a consistent 
binding of CRIT-H17 to intact FB and its two main fragments Bb and Ba, but also to 
C3b. There was no binding to FD. This unusual binding to two proteins involved in a 
mutual contact did not allow us to define the precise site involved in inhibition of AP C3 
convertase by CRIT-H17, since any one or more of these 3 bindings demonstrated might 
be involved. However the binding to Ba and Bb suggested that the small peptide CRIT-
H17 may well bind FB at the site of FB cleavage by FD.  Indeed, CRIT-H17 binds C2 
near or at the site of C2 cleavage by C1s. 
 To confirm these results, we performed a sandwich ELISA, fixing FB or C3b on 
the plates, followed by incubation with CRIT-H17 and detection of the peptide bound to 
FB or C3b with the anti-CRIT antibody. Again, CRIT-H17 bound to both FB and C3b in 
a dose dependent manner, with no binding of CRIT-H17 to albumin as a control, 
indicating specific bindings (Figure 4). Of interest was that the binding to FB appeared to 
be superior to that of C3b although a direct comparison remains difficult, not knowing 
how many binding sites are involved. 
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Figure 3  Ligand blot showing CRIT-H17 interaction with C3b and FB but not FD.  
 
CRIT-H17 (1.5 μg) was incubated with C3b (500 ng) or FB (500 ng) or FD (500 ng) or 
mixture of C3b (500 ng) and FB (500 ng) or mixture of C3b (200 ng), FB (500 ng) and 
FD (200 ng) pre-incubated for 60 min at 37°C. The resulting complexes were cross-
linked with DSS. After cross-linking, the complexes were detected by immunoblotting 
probing with polyclonal anti-CRIT antibody.  
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Figure 4  ELISA of CRIT-H17 with FB and C3b protein.  
 
Either 55 nM FB or C3b was coated on the ELISA plate and incubated with increasing 
concentration of CRIT-H17 (from 5 to 40 μM). BSA was used as control. The affinity of 
CRIT-H17 for FB is almost three times higher than C3b. Results are means±S.D. for 
three independent experiments, each with duplicate measurements. 
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Inhibition of AP activation by CRIT peptides in serum 
We have shown that CRIT-H17 could block the FD-mediated cleavage of FB in an assay 
using purified proteins, and similarly that it binds to FB and C3b when added to soluble 
mixtures. Whether these interactions would have a biological significance in a more 
physiological context was our next question. Three different peptides derived from CRIT 
were studied for their potential inhibition of the AP in a hemolytic assay specific for the 
AP and using C2 deficient serum, so as to be sure that the effects observed were not due 
to C2 inhibition. The inhibitory effects of CRIT peptides on the AP are shown in     
Figure 5. In the presence of 10 μM peptides CRIT-H17 was the best inhibitor reducing 
the lysis by 22.1% whereas the CRIT-ed1 peptide was less potent, and the peptide 
expressing the CRIT-H17 sequence twice had almost no inhibitory activity.  
 
Decay activity of CRIT-H17 on C3bBb complexes 
The complement regulatory protein DAF accelerates the decay of the C3bBb convertase 
and has been shown to interact with both FB and C3b [23, 24]. Since CRIT-H17 bound to 
both FB and C3b as well, we tested the hypothesis that CRIT-H17 would have the same 
property of dissociating C3bBb. The convertase was formed on a solid phase by binding 
first C3b, adding B in the presence of Ni2+ and Factor D. After washing, buffer alone, 
CRIT-H17 (50 μg) or DAF (5 and 10 ng) were added and the decay of the C3bBb 
complexes measured after 30 and 60 min. The results clearly showed that, unlike DAF, 
CRIT-H17 does not possess any decay activity on the dissociation of C3bBb complexes 
(Figure 6). Thus CRIT-H17 appears to have its main activity of the formation of the AP 
C3 convertase. 
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Figure 5  Inhibition of the AP activation by CRIT peptides.  
 
10 μM CRIT peptides were pre-incubated with C2-D for 30 min at RT before adding to 
the Erab. The CRIT peptides inhibited the AP C3 convertase formation by binding to FB 
or C3b or both and decreased the percentage of hemolysis. Results are means±S.D. for 
three independent experiments, each with duplicate measurements. 
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Figure 6  Effect of CRIT-H17 on Ni2+ dependent C3bBb complexes.  
 
C3bBb complexes were formed by incubating 50 ng FB and 3 ng FD in the presence of 5 
mM Ni2+ for 2 h at 37°C in C3b-coated microtiter wells. After the formation of C3bBb 
complexes, the wells were washed five times with reaction buffer and further incubated 
with buffer or CRIT-H17 or DAF for the indicated time at RT. C3bBb complexes were 
then detected by ELISA employing anti-Bb monoclonal antibody. Unlike DAF, CRIT-17 
does not have any decay activity. Results are mean±S.D. for three independent 
experiments, each with duplicate measurements. 
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CRIT-H17 reduces the FI-mediated cleavage of C3b 
As mentioned, the binding of CRIT-H17 to C3b was unexpected, but suggested that other 
aspects of the biological properties of C3b might be modified. C3b is further cleaved to 
C3bi then C3dg by FI in the presence of the correct cofactor. In Figure 7A, a schematic 
representation of C3b shows the FI cleavage sites in the presence of the cofactors, FH and 
CR1. FI cleaves C3b at the first and second cleavage sites in the presence of cofactor FH 
or CR1 to generate the 64.3 and 39.5 kDa fragments. The appearance of a smaller       
24.3 kDa fragment and C3dg indicates that FI cleaves C3b at a third site, this only in the 
presence of CR1. The pre-incubation of CRIT-H17 with C3b inhibited the FI-mediated 
cleavage in the presence of FH (Figure 7B). At the lowest dose (10μg), CRIT-H17 
showed a small reduction in the cleavage but completely blocked it at the doses of 50 and 
100 μg. CRIT-H17 could only weakly block FI cleavage of C3bi to generate the C3dg 
and 24.3 kDa fragments in the presence of CR1 (Figure 7C). CRIT-H17S, the scramble 
peptide of H17, had no inhibitory effects. The two C4β chain F212 and F222 peptides, 
showing high sequence homology to CRIT-H17, had no inhibitory effect either (data not 
shown).  
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Figure 7  Inhibition of FH and CR1 cofactor activities by CRIT-H17.  
 
(A) Schematic representation of C3b showing the FI cleavage sites in the presence of FH 
and CR1. Different amounts of either CRIT-H17 or CRIT-H17S peptides (10-100 μg) 
were pre-incubated with 500 ng C3b for 30 min at RT. After the pre-incubation, 100 ng 
FI and either 500 ng FH (B) or 500 ng CR1 (C) were added for an additional 2 h 
incubation at 37 °C. The inhibition effect of CRIT-H17 and CRIT-H17S peptides on the 
cleavage of C3b by FI were analyzed by SDS-PAGE (10 % gel under reducing condition) 
and the gel was stained with ProteoBlue staining solution. 
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DISCUSSION 
CRIT, a three transmembrane receptor first discovered on the Schistosoma parasite 
surface, acts as a decoy receptor for C2 to protect the parasite from the assembly of 
C4bC2 and the following C2 cleavage, thus preventing complement attack by the 
classical pathway [13]. This receptor was later shown to be expresses in cod fish, rat and 
human [12]. CRIT-H17 peptide proved to be the region interacting with C2 or more 
specifically with the C2 vWFA domain [15]. It is as potent inhibitor of the CP in vitro 
and in vivo [13, 14].  
 Because of the many similarities between the CP and AP C3 convertases, and the 
fact that many regulators of complement interact with both convertases, we postulated, 
that the CRIT-H17 peptide might have inhibitory effects on the formation the C3bBb 
convertase as well. Our major findings (Figure 8) were that CRIT-H17 inhibited the 
cleavage of FB by FD, probably by binding to FB, and reduced AP function. However 
additional finding were unexpected: CRIT-H17 bound also to C3b, and reduced the 
inactivation of C3b by FI whether this cleavage occurred in the presence of FH or CR1.  
 CRIT-H17 is known to bind the vWFA domain of C2, and inhibits its cleavage by 
C1s probably because the cleavage site is not any more exposed in a correct way. CRIT-
H17 bound to B, both to the Ba and the Bb fragments, suggesting that the interaction 
occurs over a region covering the FD cleavage site on FB (see Figure 8.). Of particular 
interest was that a peptide corresponding to the homologue of CRIT-H17 on the 
C4β chain blocked FB cleavage as well, although less potent than CRIT-H17. This 
finding   strengthened   the   hypothesis, that   there   are   strong   analogies  between  the  
 
 113
 
 
 
 
 
 
Figure 8  Schematic representation summarizing CRIT-mediated regulations of the 
AP C3 convertase formation.  
 
CRIT-17 interacts with both Ba and Bb fragments of FB, which in turn blocks the FD-
mediated cleavage. It’s highly possible that CRIT-H17 binds to the junction of the FD 
cleavage site. In addition, CRIT-H17 interacts with C3b and slightly inhibits the FI-
mediated cleavage of C3b in the presence of both cofactors FH and CR1. Furthermore, 
CRIT-H17, unlike DAF, does not have any decay activity of C3bBb complexes as DAF. 
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mechanisms leading to the  formation of both CP and AP C3 convertases. The 4 amino 
acid (K, H, F and S) in CRIT-H17 peptide highlighted in Figure 1 could be important for 
FB binding. Referring to the two C4β chain peptides used in this study, both of them 
have been shown to block CP activation effectively and to the same extent [13]. 
However, only C4β chain F212 peptide was able to slightly inhibit the FD-mediated 
cleavage of FB. Any of these 4 amino acid highlighted in Fig. 1 (K, Y, V and L) in C4β 
chain F212 peptide could be the important amino acid residue(s) responsible for the FB 
binding, which are also the major differences between these two C4β chain peptides. We 
postulate that these 3 amino acid residues E, V and K, in CRIT-H17 and C4β chain 
peptides are responsible for C2a binding and these 4 amino acid residues K, H, F and S in 
CRIT-H17 peptide are possibly responsible for the FB and C3b binding. In future, 
alanine positional scanning may help to further dissect out the key residue(s) responsible 
for the FB binding. Modification(s) of CRIT-H17 peptide would eventually create a 
peptide, which is more specific only towards FB, a more potent inhibitor in the AP 
activation. Referring to the sequence alignment between CRIT-H17 and C4β chain F222 
peptides in Figure 1, one interesting aspect is the additional proline residue in C4β chain 
F222 peptide, which may induce conformational change of the peptide, cis/trans 
isomerization [21, 22]. In case, we change the amino acid H→P in CRIT-H17 peptide, it 
will be interesting to test whether this modified CRIT-H17 peptide will lose its ability to 
inhibit the FD-mediated cleavage of FB.  
 The binding of CRIT-H17 to C3b appeared to be specific, since in a mixture of 
CRIT-H17, FB, C3b and FD, CRIT-H17 cross-linked only to C3b and FB. However it 
might be that the association of FB and C3b allowed some CRIT-H17 to come into near 
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contact with C3b before the cross linking agent was added. However the direct ELISA 
assay suggested that there was some affinity of CRIT-H17 for C3b, although the binding 
was much lower than for FB. Whether this binding may influence the reaction between 
C3b and FB remains unclear, since the binding of CRIT-H17 to FB might in itself modify 
the association of C3b and FB. Further experiments will be required to answer this point. 
C1-inhibitor has been shown to interfere with the activation of the AP as well by binding 
to C3, and blocking the formation of the C3bB complex. However C1-inhibitor does not 
bind FB [25]. 
 DAF regulates complement activation by accelerating the dissociation of the C3 
convertases. The mechanism of decay acceleration of DAF is still unknown. In 1996, 
Kuttner-Kondo et al. [26] proposed a molecular model and mechanism of action of DAF. 
In this model, DAF and Ba fragment of FB share a common binding site on C3b. FB 
binds to C3b and the Ba fragment of FB is released from the complex after FD cleavage. 
After the release of Ba fragment from C3b, DAF binds to the Ba binding site on C3b. 
Upon the binding of DAF, Bb fragment is destabilized and released. CRIT-H17 did not 
modify the decay of the C3bBb convertase, despite its binding to purified Bb and C3b. 
Thus the mechanism by which CRIT-H17 inhibits the AP in serum does not include the 
decay of the convertase, and indicates interactions with C3b and Bb very different from 
DAF.  
 The FI mediated cleavage of C3b to iC3b then to C3dg requires the binding of a 
cofactor to C3b (FH or CR1). CRIT-H17 reduced the activity of both cofactors, 
suggesting that the observed binding to C3b was not without consequences, although 
alternatives cannot be excluded: direct inhibition of FI, or interference with CR1 or FH 
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function. Many more studies have to be done to answer this question, but the main aspect 
worth underlining is that CRIT-H17 had properties in vitro suggesting multiple 
interactions regulating the AP. The assay of CRIT-H17 in whole serum suggested that the 
sum of the different observations made here lead to inhibition of the AP. This inhibition 
was however much lower than the blockade of the activation of the CP [13]. 
 To study CRIT-H17-Ba/Bb and CRIT-H17-C3b interactions more precisely, 
structural studies by NMR or X-ray crystallography should be carried out. The structural 
data will enable us to firmly predict which residues are more likely to be involved in 
these protein-protein interactions and further understand the mode of regulatory actions 
of CRIT-H17 peptide in the AP activation. Dissecting out the interaction region of CRIT-
H17-Ba/Bb, the SCR 3 region of Ba and the vWFA domain of Bb will be the best place 
to start with. Kuttner-Kondo et al. [26] has predicted with his model that the SCR 3 of Ba 
would be an important region for interacting with C3b. Previously, we have shown that a 
CRIT binding site presents in C2 vWFA domain [15]. Because of the sequence homology 
between C2 vWFA and FB vWFA domains, we predict CRIT-H17 peptide interacts with 
Bb fragment of FB via the vWFA domain. In addition, binding of CRIT-H17 peptide to 
FB could inhibit the FD cleavage. Thus, CRIT-H17 peptide should bind to the region 
near to the FD cleavage site. The SCR 3 of Ba and vWFA domain of Bb should be a right 
guess. For CRIT-H17-C3b interaction, it’s more difficult to assign the potential region of 
interaction.  However, since CRIT-H17 peptide could inhibit the FI-mediated cleavage of 
C3b in the presence of FH and CR1, we can assume CRIT-H17 peptide binds to the C3α 
chain, the region close to the first, second and third FI cleavage sites. Expressing the 
recombinant proteins of Ba (or SCR 3), the vWFA domain of Bb and C3α chain can be 
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used for functional studies or complexed with CRIT-H17 peptide for structural studies by 
X-ray crystallography 
 In summary, the data present evidences that CRIT-H17 peptide, proved to be a 
potent inhibitor of the CP, also functions as a regulator in the AP. The AP has been 
proved to be important in various diseases. Developing a specific AP inhibitor should be 
therapeutically important in the future. Alanine positional scanning and structural studies 
will provide an insight and invaluable information about the mode of regulatory actions 
of CRIT in the AP. The most important issue will be the opportunity to modify and create 
a more specific and potent AP inhibitor.    
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CONCLUSION AND FUTURE PERSPECTIVES 
 
The novel complement regulator, CRIT, previously described in the Schistosoma parasite 
was cloned and the partial sequence of cod CRIT and full-length sequences of rat and 
human CRIT were obtained by PCR [1], as well as that of Trypanosoma cruzi. The 
human CRIT nucleotide sequences from genomic DNA and cDNA are identical, 
implying that human CRIT is encoded by a single exon, and is intronless gene. When 
comparing the human CRIT nucleotide sequence with rat, it shows 82 % homology. 
Western blotting showed expression of human CRIT in various hemopoietic cells as well 
as platelets, monocytes, dendritic cells and lymphocytes. The distribution of CRIT 
receptor in various human tissues was determined by immunohistochemistry and CRIT 
was found in pancreas, proliferating endometrium, esophagus, kidney, and testis.  
  
The expression of the recombinant vWFA domain of C2 was proved difficult, and the use 
of similar strategies as had been used to express its functional homologue, FB, has not 
worked well [2]. After many unsuccessful trials, we managed to express the first 
functional recombinant vWFA domain of C2. This recombinant C2 vWFA protein 
provides an ultimate chance to further dissect out the fine interaction between C2a and 
CRIT or C4b. The results presented in Section II clearly demonstrate that there is one 
CRIT binding site on the C2 vWFA domain [3]. In addition, by sandwich ELISA and 
pull-down assay, we further confirm that C2 vWFA domain contains a C4 binding site. 
C4 binds to C2 vWFA domain mainly via its β chain. However, further studies need to be 
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performed to clearly elucidate whether CRIT and C4 share the same binding site on C2 
vWFA domain.  
 
CRIT inhibits the CP C3 convertase formation by competing with C4 for the binding of 
C2, which in turn, blocks the C1s cleavage of C2 [4]. Besides the inhibitory effect on the 
CP, CRIT also functions as a regulator in the AP by binding to FB and in turn blocking 
cleavage of FB. However, the inhibitory effect of CRIT on the AP is much weaker than 
on the CP. As a result of this study, an unexpected observation was made. Besides 
binding to FB, CRIT also bound to C3b. In addition, CRIT inhibits partially the FI-
mediated cleavage of C3b in the presence of both cofactors CR1 and FH. We postulate 
that CRIT binds to the C3α chain, the region close to the FI cleavage sites, and in turn 
blocks the FI cleavage or it interferes with the ability of cofactors to bind C3b. Compared 
to the relative binding affinity between CRIT-FB and CRIT-C3b, based on the ELISA 
data, the binding to FB is almost three-fold higher than to C3b. Even though the binding 
of CRIT to C3b is weak, the influence of CRIT-C3b binding on FB and on the inhibition 
of the AP C3 convertase formation remains unknown. The overall CRIT-mediated 
regulations of both the CP and AP are summarized in Figure 1. 
  
Besides the initiating factor, the CP and MBL-P are identical. We also tested whether 
CRIT would have any effect on the MBL-P. Based on the unpublished data (Figure 2), 
CRIT could block the MBL-P, with similar potency as the CP, in an ELISA-based 
hemolytic assay. Since MASP-2 is structurally and functionally similar to C1s, the 
binding of  CRIT to C2 could probably block the MASP-2 cleavage  of  C2, in  the same   
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Figure 1  Schematic representation summarizing CRIT-mediated regulations of 
both the CP and AP C3 convertases formation.  
 
In the AP, CRIT-H17 peptide interacts with FB, both Ba and Bb fragments, which in turn 
blocks the FD-mediated cleavage. In addition, it interacts with C3b and slightly inhibits 
the FI-mediated cleavage of C3b in the presence of cofactors FH and CR1. Unlike DAF, 
CRIT-H17 doesn’t have any decay activity of C3bBb complex. In the CP, CRIT-H17 
binds to C2, mainly to vWFA domain, and blocks the C1s cleavage, which in turn blocks 
the assembly of the CP C3 convertase, C4bC2a. C2 vWFA domain contains both C4 and 
CRIT binding site(s) and C4 binds to C2 vWFA mainly via its β-chain. The red crosses 
mean inhibitory effect of CRIT-H17 on the CP or AP. 
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Figure 2  Comparison between the inhibitory effect of CRIT-H17 on the CP and 
MBL-P 
 
Different amounts of CRIT-H17 were pre-incubated with normal human serum for        
30 min at RT before adding to the ELISA well (CP; coated with IgM, MBL-P; coated 
with mannan). The inhibitory effect of CRIT-H17 on C5b-9 complex was detected with a 
specific alkaline phosphate labeled antibody to the neoantigen expressed during MAC 
formation.  
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way as C1s in the CP. Thus, CRIT can block the MBL-P derived C3 convertase 
formation. However, further experiments need to be done to confirm this result. 
  
Since CRIT interacts with more than one complement components, it will be interesting 
to perform the kinetic analysis of protein-protein interactions between CRIT and C2 or 
FB or C3b, both parallel and competitive reactions, by surface plasmon resonance 
biosensors [2, 5, 6]. The kinetic data should give an insight into the mode of regulation of 
CRIT in the complement systems.  
 
WFA (often called an I domain in integrins) domain are a family comprising molecules 
of approximately 200 amino acids with a highly conserved MIDAS (metal-ion-dependent 
adhesion site) motif. Most of the well-characterized vWFA domains are found in 
extracellular matrix (ECM) [7] and are the sites of protein-protein interaction in cell-
adhesion protein, such as integrins [8, 9]. All integrin β subunits and nine known integrin 
α subunits (α1, α2, α10, α11, αD, αE, αL, αM and αX) contain vWFA domain [7, 10]. 
The MIDAS motif is involved in integrin-ligand interaction [11] with a mutual 
coordination of metal ion [12]. Integrins play an important role in cell-cell and cell-ECM 
interaction, which for example mediate cell growth and differentiation, tumor growth and 
metastasis. Integrin inhibitors, such as disintegrins and α2β1 integrin inhibitor, play an 
important role in the treatment and prevention of thrombosis and cancer [13]. Since CRIT 
interacts with the C2 vWFA domain and the interaction point is predicted to be close to 
the MIDAS motif, this raises one interesting question: will CRIT interact with integrin(s) 
via the vWFA domain or the highly conserved MIDAS motif? If the answer is YES, it 
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will be interesting to test in the near future to see whether CRIT, besides acting as 
complement regulator, can also function as an integrin inhibitor.  
 
CRIT receptor expresses in a wide range of cells and tissues and even though the latest 
studies indicate that CRIT is involved in signal transduction and endocytosis from the 
cell surface [14], very little is known about its other functional properties. The expression 
of CRIT on platelets and endothelial cells may play an important role in the prevention of 
thrombus formation, if CRIT can bind to collagen exposed at the site of damaged 
endothelial cell surface and in turn, prevent blood platelets from adhering to collagen and 
subsequent activation of blood platelets. In addition, the expression of CRIT on 
monocytes may play a role in the differentiation of monocytes into macrophages.  
 
In the future, functional studies should be carried out to further characterize this novel 
membrane receptor, CRIT. Yeast two-hybrid and phage display library screening should 
help to fish out any potential interaction partners. Structural studies and alanine positional 
scanning will provide an insight into the site of interaction between CRIT and the 
complement components, C2, FB and C3b. Furthermore, it provides invaluable 
information on the design and modifications of CRIT peptide so as to create a more 
specific and potent complement inhibitor.     
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